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Autoimmune diseases occur when the immune system attacks and damages the body’s 
own tissue. Why people develop these diseases, and how the autoimmune reaction 
develops are unanswered questions. Autoimmune Addison's disease (AAD) is an 
organ-specific autoimmune disorder characterized by an immunological attack of the 
adrenal cortex. The complex genetic architecture underlying AAD has not been entirely 
established, and the overall aim of this project was therefore to identify and 
functionally characterize genetic risk factors in AAD.  
We discovered several rare and damaging inborn errors of antiviral immunity in AAD 
patients. Among them, variants in the gene encoding Toll-like receptor 3 (TLR3), 
which recognizes double-stranded RNAs (dsRNAs) upon viral infection. Functional 
characterization of the TLR3 variants revealed a partial loss of function effect on the 
receptor’s signaling activity, leading to impaired interferon (IFN) responses ex vivo.  
Next, we identified a homozygous stop-gain variant in the gene encoding 3β-
hydroxysteroid dehydrogenase type 2 (3βHSD2), causing a rare form of congenital 
adrenal hyperplasia (CAH). The mutation was carried by an AAD patient with 
circulating antibodies against the major AAD autoantigen 21-hydroxylase (21OH). To 
our knowledge, this combination represents a novel disease etiology.  
Finally, we wanted to identify HLA-specific immunodominant epitopes of 21OH, 
targeted by autoreactive T cells. We discovered a new immunodominant epitope, 
ARLELFVVL (21OH434-442), presented by HLA-C*0701. This is the first HLA-
C*0701 restricted epitope described for a self-antigen in an autoimmune disease. We 
also confirmed the presence of autoreactive CD8+ T cells responses to the previously 
proposed epitope LLNATIAEV (21OH342-350), restricted to HLA-A2.  
Altogether, the work in this doctoral dissertation has provided new insights 
into why certain individuals might be more genetically susceptible to develop AAD, 
and partly how the autoimmune reaction progresses.  
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Introduction 
Protection against invasive pathogens is fully dependent on the immune system, a 
highly evolved network of specialized cells and molecules. This host defense system 
is remarkably effective as serious persistent infections are quite rare. Nonetheless, there 
are some limitations in that severe infections occasionally may occur, and also, in that 
the immune response sometimes fails to discriminate self from non-self, causing 
autoimmunity.  
The development of autoimmunity recapitulates the same immune responses used to 
fight off infections and results in destruction of the host’s own cells and tissues. 
Autoimmune disorders may affect almost all organs, whereby the clinical phenotype 
and severity are dependent on which tissue is being attacked. In autoimmune Addison’s 
disease (AAD), the immune system is directed against the hormone-producing cells of 
the adrenal cortex, leading to insufficient production of vital steroids. Patients with 
Addison’s disease therefore depend upon lifelong replacement therapy [1].  
In the following, a brief introduction of the main components of the immune system is 
given, followed by a description of immunological tolerance and autoimmunity with 
emphasis on AAD.  
The innate and adaptive immune system 
To establish an infection, the pathogen must break through the first line of defense 
consisting of the skin and mucous barriers that secretes chemical compounds restricting 
the adherence and growth of microbes. Pathogens that manage to overcome these 
barriers will meet the two further lines of defense, the innate and adaptive immune 
systems [2].  
The components constituting the innate immune response may be found in all advanced 
living organisms and has been refined for a longer period throughout evolution than 
the adaptive immune system, which is believed to have arisen with the vertebrate 
lineage [3, 4]. The innate immune system mounts the same immediate response each 
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time it gets exposed to a certain pathogen, whereas the adaptive immune response will 
improve on every exposure to the same pathogen, making it antigen-specific.  
The cellular components of innate immunity 
The innate immune response is largely dependent on phagocytosis by mononuclear and 
polymorphonuclear phagocytes. The mononuclear phagocytes include monocytes, 
dendritic cells (DCs), and macrophages. DCs are professional antigen-presenting cells 
(APCs) that can activate immune cells of the adaptive immunity and are found in most 
tissues including lymphoid organs, skin, lung, and kidneys [3, 5]. Macrophages are 
specialized cells that engulf and destroy any foreign invader, as well as clearing up 
debris from dead cells, and are located within the parenchyma of major organs 
throughout the body. They also serve as APCs to activate adaptive immune responses. 
Upon recognition of a pathogen, macrophages release chemotactic cytokines to attract 
other phagocytes, in particular polymorphonuclear phagocytes, to the site of infection. 
The polymorphonuclear myeloid cells (also known as granulocytes) include 
neutrophils and eosinophils, releasing reactive oxygen species to kill bacteria and 
parasites, in addition to basophils and mast cells, the main mediators of inflammation 
and allergic responses [2]. Another important cell population of innate immunity is the 
innate lymphoid cells (ILCs). ILCs respond quickly to pathogens by producing various 
cytokines and are especially abundant at mucosal surfaces [6]. ILCs include the natural 
killer (NK) cells that can kill infected and malignant cells, in addition to produce 
diverse cytokines such as interferon gamma (IFNγ) and tumor necrosis factor alpha 
(TNFα) [7]. To further control the spreading of microorganisms, the complement 
system is activated, involving acute phase proteins in the blood that mediate 
opsonization and lysis of the pathogen, in addition to enhancing the inflammatory 
response [8].  
To recognize pathogens, the innate immune system uses pattern recognition receptors 
(PRRs) that are specialized to detect small molecules deriving from viruses, fungi, 
bacteria, and protozoa, known as pathogen-associated molecular patterns (PAMPs) [9]. 
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Binding of PAMPs to PRRs will activate numerous different signaling pathways that 
produce cytokines promoting the host response to infection [10, 11].  
Innate immune receptors 
The existence of PAMPs has been known for decades, but the PRRs recognizing them 
were introduced more recently by Charles Janeway in 1989 [12]. Since then, several 
classes of PRRs have been discovered including Toll-like receptors (TLRs), 
nucleotide-binding oligomerization domain (NOD)-like receptors (NLRs), retinoic 
acid-inducible gene I (RIG-I)-like receptors (RLRs), C-type lectin receptors (CLRs) 
and AIM2-like receptors (ALRs). These receptors are categorized by their structure 
and specificity, in addition to their tissue-specific expression and cellular localization 
[11]. The best characterized PRRs are the TLRs, and at present ten functional human 
TLRs have been defined. TLR1, TLR2, TLR4, TLR5, TLR6, and probably TLR10 are 
all expressed on the cell surface, detecting extracellular components of bacterial and 
fungal cell walls, such as lipopolysaccharides (LPS), di– and triacyl lipopeptides, 
peptidoglycan (PGN) and flagellin. The remaining TLR3, TLR7, TLR8, and TLR9 are 
localized within endosomes, where they detect foreign nucleic acids such as double-
stranded ribonucleic acid (dsRNA), single-stranded RNA (ssRNA) and unmethylated 
CpG deoxyribonucleic acid (DNA), respectively. These intracellular TLRs are believed 
to function primarily as viral sensors (Figure 1) [9, 11].  
Activation of intracellular TLR signaling is induced by binding of the ligand to the 
leucine-rich repeats of the receptors’ ectodomain. For all TLRs except TLR3, this leads 
to activation of the adaptor protein myeloid differentiation primary response 88 
(MyD88). MyD88 then interacts with interleukin (IL)-1R-associated kinase-4 
(IRAK4), which phosphorylates IRAK1 and IRAK2 that, in turn, activate TNF 
receptor-associated factor 6 (TRAF6) [9, 13]. TRAF6 is further involved in activation 
of the mitogen-activated kinase (MAPK) pathway, and the two transcription factors 
nuclear factor-kappa B (NF-kB) and IFN regulatory factor 7 (IRF7), leading to the 
production of antiviral and proinflammatory cytokines like TNF, IL-12 and IL-6, and 
type I and III IFNs [14-16].  
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Upon TLR3 signaling, MyD88 is substituted with the adaptor protein TIR-domain-
containing adapter-inducing IFN-β (TRIF), which interacts with both TRAF3 and 
TRAF6. TRAF3 links TANK-binding kinase 1 (TBK1) with inhibitor of NF-kB kinase 
subunit epsilon (IKKε), which together phosphorylate IRF3, leading to the production 
of type I and III IFNs. TRAF6, as mentioned earlier, induces transcription of 
proinflammatory cytokines and IFNs [14]. [17] 
 
 
Figure 1. TLR signaling pathways. The extracellular TLRs (TLR1, TLR2, TLR4, TLR5, 
TLR6, and probably TLR10) are activated by molecules deriving from bacterial and fungal 
cell walls including lipopolysaccharides (LPS), di- and triacyl lipopeptides, peptidoglycan 
(PGN) and flagellin. The intracellular TLR3, TLR7, TLR8, and TLR9 are activated by nucleic 
acids within endosomes. Binding of the ligand to the receptors’ ectodomain induces activation 
of the adaptor proteins MyD88 or TRIF. MyD88 recruits IRAK4 to phosphorylate IRAK1 and 
IRAK2, which further phosphorylate TRAF6, leading to activation of the IKK complex 
(IKKγ, IKKα, and IKKβ). This complex activates NF-kB, allowing it to translocate into the 
nucleus and initiate the production of pro-inflammatory cytokines. The other adaptor protein 
TRIF interacts with both TRAF3 and TRAF6. TRAF3 links TBK1 with IKKε, which 
promotes phosphorylation of IRF3 and IRF7, leading to the production of type I and III IFNs. 
The TLRs generally form homodimers upon activation, whereas TLR2 also functions as a 





Apart from the TLRs, RLRs also sense viral RNA products, not within endosomes, but 
in the cytosol of infected cells. RIG-I and melanoma differentiation-associated gene 5 
(MDA5) are two well-defined RLRs, and activate NF-kB and IFN production through 
the same signaling pathways utilized by the TLRs [18].  
Newly synthesized type I IFNs (α and β) and type III IFN (λ) will engage their cognate 
receptors to activate the Janus kinase/signal transducers and activators of transcription 
(JAK/STAT) signaling pathway. The result is the expression of IFN-stimulated genes 
(ISGs), which induce an antiviral state involving RNA degradation, inhibition of 
protein synthesis, upregulation of major histocompatibility complex (MHC) class I 
(described later), chemokine secretion, and apoptosis [19-22].  
The adaptive immune system 
While the innate immunity mediates a rapid response to infectious agents, the range of 
innate sensors recognizing them is limited. Consequently, an adaptive and more 
specific recognition system has evolved, providing a broader repertoire for detecting 
constantly mutating microbes. Also, after the initial exposure, the adaptive immune 
response develops memory cells with the capacity of mediating a rapid and enhanced 
response upon re-exposure to the same pathogen [23].  
Cells of the adaptive immune system include thymus-derived T lymphocytes and bone 
marrow-derived B lymphocytes. During their development, they acquire T cell 
receptors (TCRs) and B cell receptors (BCRs), respectively, which enable them to 
recognize a wide range of antigens. The receptors are generated by random 
combinations of gene segments that are both variable and constant, giving rise to a 
wide T and B cell repertoire [2]. Following their development in the thymus and bone 
marrow, T and B cells migrate to secondary lymphoid organs for activation and 
proliferation. Activation is initiated upon binding of antigens by TCRs and BCRs, 
presented by professional APCs, in particular DCs, that have migrated to secondary 
lymphoid organs. The lymphocytes then migrate to the sites of infection and work 
together with the innate immunity to eliminate the pathogen [23]. There are two types 
of adaptive immune responses: the humoral response involving antigen-specific 
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antibodies produced by plasma cells (terminally differentiated B cells), and the cell-
mediated response mediated by T cells, which destroys infected cells [24]. 
T cells 
T cells can be divided into two main subsets based on their expression of either cluster 
of differentiation (CD) 8 or CD4 [25]. CD8+ T cells interact with antigen peptides 
presented by MHC class I molecules expressed by all nucleated cells, whereas CD4+ T 
cells interact with antigens presented by MHC class II molecules mainly restricted to 
APCs. The MHC proteins are encoded by the human leukocyte antigen (HLA) system 
including class I genes (HLA-A, HLA-B, and HLA-C) and class II genes (HLA-DR, 
HLA-DQ, and HLA-DP) [23]. In addition to antigen stimuli (signal 1), co-stimulatory 
signaling is required for T cell activation, involving the interaction of CD80/CD86 on 
APCs with CD28 on T cells (signal 2), as well as inflammatory cytokines (such as IL-
12 or IFNα/β) (signal 3) (Figure 2). The co-stimulatory signal is finely tuned by 
inhibitory receptors including cytotoxic T lymphocyte-associated protein 4 (CTLA-4) 
and programmed cell death protein 1 (PD1) [26].  
Following these stimulating events, the production of IL-2 is induced and CD8+ T and 
CD4+ T cells differentiate into functionally distinct effector populations. Naïve CD4+ 
T cells, also known as T helper (Th) cells, develop into either Th1, Th2, or Th17 
depending on the surrounding cytokine milieu mediated by innate immune cells. IL-12 
results in differentiation toward Th1 cells, which support cell-mediated responses in 
which they secrete IFNγ and IL-2 to activate macrophages and CD8+ T cell 
development (Figure 2). IL-4 induces differentiation towards Th2 cells that stimulate 
humoral and allergic responses by releasing IL-4, IL-5, IL-10, and IL-13 [23, 24, 27, 
28]. Transforming growth factor-beta (TGF-β) and IL-6 promote the development of 
Th17 cells, which secrete IL-17 important for protection against extracellular fungi and 
bacteria. Notably, Th17 cells are known to be implicated in the disease progression of 
several autoimmune disorders such as rheumatoid arthritis (RA), systemic lupus 
erythematosus (SLE), and psoriasis [29, 30]. In addition to Th17 cell development, 
TGF-β, accompanied by IL-2, induces differentiation towards regulatory T cells 
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(Tregs), critical for regulating T-cell responses through anti-inflammatory cytokines, 
such as IL-10 [31].  
 
 
Activation of naïve CD8+ T cells results in the conversion to cytotoxic T cells that are 
essential for defeating pathogens (mostly viruses) in the cytosol of infected cells. Once 
they are activated, they produce IFNγ to stimulate their cytotoxicity and motility, 
enabling them to efficiently colonize sites of inflammation [32]. Importantly, IFNγ 
production is associated with several autoimmune diseases including SLE and AAD 
[33-35]. Following migration to the site of inflammation, cytotoxic T cells recognize 
antigens presented by MHC class I molecules on the surface of target cells and kill 
them by mediating the coordinated action of perforin and granzymes. Perforin 
Figure 2. A simplified schematic of T cell activation. Extracellular antigens are taken up 
by an APC, in this figure a DC, and presented to CD4+ T cells via class II MHC molecules 
and CD8+ T cells via class I MHC molecules (Signal 1). For proper T cell activation, co-
stimulatory signals are required, involving the interaction of CD80/CD86 on the APC with 
CD28 on the T cells (Signal 2), as well as inflammatory cytokines produced by the APC 
(Signal 3). Release of cytokine IL-12 will push the CD4+ T cell into the Th1 type, which, in 
turn, will secrete cytokines, such as IL-2, to support T cell proliferation and differentiation. 
Figure produced using Medical Servier Art. 
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generates pores in the membrane of the target cell, allowing granzymes to enter and 
activate a caspase cascade. Ligation of Fas-ligand on the cytotoxic T cell to Fas 
receptors on the target cell can also induce apoptosis, although this mechanism 
functions mainly to delete activated Fas-expressing lymphocytes after an infection has 
been cleared, to maintain lymphocyte homeostasis [23, 36].  
B cells and antibodies 
The adaptive humoral response is mediated by antibody-producing plasma cells 
developed from B cells. In the bone marrow, B cells pass through several 
differentiation stages involving rearrangements of the genes encoding antibody, or 
immunoglobulin (Ig), heavy and light chains to become IgD and IgM-expressing cells. 
This stage does not require contact with exogenous antigens and is therefore called 
antigen-independent B cell development [23]. In the next phase, B cells migrate to 
secondary lymphoid organs to finalize their Ig repertoire. This development stage is 
mainly dependent on the ability of B cells to function as APCs. The IgM and IgG 
receptors capture antigens and internalize them for further presentation by MHC class 
II molecules on the B cell surface. When the B cell then interacts with a T cell, in 
particular a Th cell specific for the MHC class II/antigen, the T cell starts producing 
cytokines to promote B cell proliferation. Subsequent interaction between CD40L on 
T cells and CD40 on B cells promotes differentiation of B cells into short-lived - or 
memory plasma cells, as well as Ig class switching from IgM and IgD to IgG, IgA or 
IgE, depending on the surrounding cytokine milieu [23, 27].  
Immunological tolerance  
Cells of the adaptive immunity are shaped to recognize and neutralize an infinite 
number of pathogens. Inevitably, some of their receptors may also react to host 
components. T and B cells must therefore undergo immunological tolerance enabling 
them to discriminate between self and non-self. There are two mechanisms by which 
immunological tolerance occurs: i) during lymphocyte maturation in the primary 
lymphoid organs (central tolerance); ii) during lymphocyte-antigen interactions in the 
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secondary lymphoid organs (peripheral tolerance). If these mechanisms fail, 
lymphocytes may start to attack cells of our own body resulting in autoimmunity [37, 
38].  
Central tolerance 
The process of central B cell tolerance is thought to be less complex than the one for T 
cells. Immature B cells that display self-reactive receptors in the bone marrow either 
undergo apoptosis or get the chance to rearrange their receptors’ specificity to become 
less self-reactive, resulting in survival [38]. On the other hand, T cells are required to 
pass through two tolerance mechanisms: positive- and negative selection. Positive 
selection represents the first step where only double-positive T cells (CD4+CD8+) 
showing a defined affinity to self MHC molecules survive. Those without any affinity, 
constituting 90% of all double-positive cells, undergo a death pathway called “death 
by neglect” [39]. Following positive selection, double-positive T cells differentiate into 
single-positive cells (either CD4+ or CD8+) before subjected to negative selection in the 
thymic medulla. Here, they encounter a variety of self-antigens by interacting with 
medullary stromal cells including medullary thymic epithelial cells (mTECs) [40]. By 
utilizing promiscuous gene expression, mTECs and other APCs in the thymus express 
and present numerous peripheral tissue-specific antigens [41, 42]. These antigens 
represent diverse tissues such as the lung, heart, stomach, and kidney, and their 
expression is regulated by the key transcription factor “autoimmune regulator” (AIRE). 
AIRE is therefore a critical regulator of central tolerance, and deficiency causes 
autoimmune destruction of several, mostly endocrine, organs manifesting as the 
syndrome autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy 
(APECED), also known as autoimmune polyendocrine syndrome type-1 (APS-1) [43, 
44]. Besides this well-established role for AIRE in negative selection, there is 
increasing evidence that AIRE also promotes thymic Treg development [45]. A recent 
study of Aire-deficient mice showed that AIRE promotes the generation of 
Foxp3+CD4+ Tregs in the perinatal period [46]. Given this influence, it has been 
speculated that Treg defects caused by AIRE deficiency might contribute to 
autoimmunity [45]. However, this hypothesis requires further testing.  
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After surviving both positive and negative selection, the remaining CD4+ and CD8+ T 
cells expressing TCRs without high affinity for self-peptides, migrate to the periphery 
and secondary lymphoid organs where they have the potential to interact with their 
cognate antigens presented by APCs [37].  
Peripheral tolerance 
Although central tolerance is thought to be efficient, some self-reactive lymphocytes 
manage to escape deletion in the primary lymphoid organs. Thus, peripheral tolerance 
has evolved to serve as a second elimination process in the periphery. This mechanism 
is based upon the principle that any escaping self-reactive lymphocyte would need to 
find a cooperating partner for sufficient co-stimulation and activation. In the absence 
of such cooperation, autoreactive lymphocytes enter an inactive state, known as anergy, 
which remains even if they re-encounter the same antigen under appropriate stimuli. 
For autoreactive B cells, anergy is induced when they interact with self-antigens 
without finding a cooperating Th cell. In this condition, B cells are outcompeted by 
other B cell clones and become excluded from entering the lymphoid follicles to 
receive survival factors [37, 47].  
When self-reactive T cells escape negative selection, peripheral tolerance is promoted 
by at least three distinct mechanisms: i) anergy; ii) deletion by activation-induced cell 
death; iii) immune suppression by Tregs [37]. Anergy is induced, as previously 
mentioned, when the TCR encounters antigens in the absence of co-stimulation. It can 
also be induced by binding of CD80/CD86 on APCs to CTLA-4 on T cells, which 
transmits an inhibitory signal [48, 49]. The second mechanism, deletion by activation-
induced cell death, is induced when Fas (CD95) and FasL (CD95L) on T cells interact 
after repeated stimulation of the TCR [50]. The last peripheral tolerance process is 
mediated by Tregs, which suppress T cell responses either in a contact-dependent 
manner or by producing immunosuppressive cytokines such as TGF-β or IL-10 [51]. 
Tregs are therefore important for maintaining self-tolerance, which is underlined by 
previous research showing that decrease in their numbers and function is associated 
with several autoimmune disorders such as SLE, multiple sclerosis (MS), type 1 
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diabetes (T1D), APS-1, RA, and immune dysregulation, polyendocrinopathy and 
enteropathy, X-linked (IPEX) syndrome [52-54].  
Autoimmunity  
From the brief overview of immunological tolerance above, it appears that 
autoimmunity is a result of defective elimination of self-reactive lymphocytes. Once 
some of these autoreactive lymphocytes are activated, multiple parts of the immune 
system may get involved in attacking host tissue, leading to either systemic or organ-
specific autoimmune disorders. So far, more than 80 autoimmune disorders have been 
described, and their incidence and prevalence are still rising [55]. Some of them seem 
to have shared, yet complex, genetic bases and etiology pathways as they often tend to 
co-occur within individuals and families [56]. However, they may only develop after 
exposure to certain environmental factors, making them challenging to study and fully 
understand.  
Genetic factors 
Several genetic risk factors for autoimmunity have been identified, but their precise 
contribution is often hard to specify. Nonetheless, a few autoimmune disorders are 
induced by single gene alterations, making them easier to study and diagnose. One 
classic example is the unique disorder APS-1 caused by both autosomal recessive 
mutations and dominant-negative mutations in AIRE [44, 57, 58]. Another example is 
the autoimmune lymphoproliferative syndrome, also known as the Canale-Smith 
syndrome, caused by impairment of Fas-induced apoptosis, due to mutations in the 
FAS gene or other genes involved in apoptosis [59]. The IPEX syndrome is also a 
monogenic autoimmune disease, caused by mutations in forkhead box P3 (FOXP3) 
that regulates the development and suppressive activity of Tregs [60, 61].  
Apart from these disorders, most autoimmune diseases are polygenic, resulting from 
multiple susceptibility variants in many genes. The best-characterized genetic 
component so far is mapped to the HLA locus encoding class I or II MHC molecules. 
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Several associations between polymorphisms in the HLA complex and autoimmune 
diseases have been described. For instance, the haplotypes DRB1*03:01-DQA1*05:01-
DQB1*02:01 and DRB1*04:04-DQA1*03:01-DQB1*03:02 (DR3-DQ2 and DR4-
DQ8) are shown to confer risk to both celiac disease (CD), T1D, autoimmune thyroid 
disease (AITD), and AAD, explaining why these diseases tend to co-occur within 
individuals [43, 62, 63]. CD is nonetheless considered one of the most evident HLA-
associated diseases as it occurs selectively in individuals expressing the DQ2 or DQ8 
haplotypes [64, 65]. In conjunction, specific HLA alleles seem also to be involved in 
drug-induced autoimmunity by abacavir, an anti-retroviral medication used to treat 
human immunodeficiency virus (HIV). In treated individuals expressing the HLA-
B*57:01, abacavir seems to alter the binding cleft of the HLA class I molecule, 
increasing self-epitope binding. This leads to autoreactive T cell responses and 
abacavir hypersensitivity reactions [66, 67].  
The role of certain HLA alleles in the pathogenesis of autoimmunity is most probably 
related to their antigen-presenting capacity; either by enhancing peptide-presentation 
in the periphery, leading to increased activation of T cells or by an insufficient 
presentation of self-antigens in the thymus, resulting in more self-reactive T cells or 
fewer Tregs [68, 69]. Apart from the HLA locus, several other autoimmune 
susceptibility genes have been identified, encoding cytokines, costimulatory 
molecules, molecules involved in promoting apoptosis, members of cytokine- or 
antigen-signaling cascades, and molecules that clear antigen or antigen-antibody 
complexes [70]. None of these genetic risk factors, however, can alone induce 
autoimmunity as it is the overall genetic background of the host that determines the 
probability of disease development [70].  
Autoimmune susceptibility genes can also increase immunoreactivity, but they may 
not necessarily lead to an improved immune response against pathogens. In fact, 
individuals with autoimmune disorders show increased susceptibility to infections, and 
manifestations of autoimmunity may only occur after exposure to certain pathogens 
[71, 72]. This is mirrored by the high degree of genetic overlap between autoimmune 
disorders and monogenic primary immunodeficiency diseases (PIDs). Variations in the 
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PID genes including AIRE, STATs, FOXP3, LRBA (lipopolysaccharide responsive 
beige-like anchor), and CTLA4 are reported to be involved in the immune dysregulation 
of several autoimmune diseases including APS-1, IPEX, T1D, RA, vitiligo and AITD 
[73, 74]. Patients with PID caused by mutations in these genes are also prone to develop 
autoimmune diseases. Therefore, a major reason for autoimmunity could be the lack of 
clearance of microbial antigens, implying the impact of environmental triggers.  
A useful tool for studying the relative contribution of genetic and environmental factors 
in autoimmune diseases is twin studies. In CD and AAD, the concordance rates among 
monozygotic twins are 75-86% [75, 76] and 71% [77] respectively, whereas RA and 
systemic sclerosis have less concordance [78], suggesting higher involvement of 
environmental factors. Moreover, a true twin concordance rate may only develop after 
several years, meaning that monozygotic twins have different disease onsets, also 
suggesting the involvement of non-genetic factors [78]. Another compelling evidence 
for an environmental contribution is the genotype-independent geographic variation of 
β-cell autoimmunity involved in T1D [79].  
Environmental factors 
The well-known environmental factors associated with autoimmunity include 
infections, vaccines, hormones, chemical exposures, drugs, diet, and cigarette smoking 
[80-82]. Among these, the most compelling and studied one is infection caused by 
viruses, bacteria, and other pathogens [83]. Several mechanisms of how infections 
induce autoimmune responses have been proposed. The pathogen may carry epitopes 
that are similar to the host’s antigens, a phenomenon termed “molecular mimicry”. 
Lymphocytes that react to such epitopes may then also react to self-antigens, resulting 
in tissue damage and activation of other parts of the immune system. Another 
mechanism is “epitope spreading”, whereby the host tissue is damaged by the immune 
response to a persistent infection, and/or by necrosis caused by the pathogen itself. 
Self-antigens are then released, leading to local activation of APCs and presentation of 
self-peptides that further activate autoreactive lymphocytes. Activation and stimulation 
of these lymphocytes may also be indirect or non-specific, caused by inflammation 
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present during an infection, a mechanism called “bystander activation” involving 
“cryptic antigens” [84]. In contrast to dominant antigens, cryptic antigens are usually 
invisible to the immune system as they appear in low concentrations. Upon 
inflammation, however, their concentration can increase due to elevated production of 
proteases and differential processing of released self-peptides by APCs [85, 86]. This 
creates the opportunity for autoreactive lymphocytes to develop. 
The role of infection underlying autoimmune responses has especially been assigned 
to T1D, MS, and autoimmune liver disease or autoimmune hepatitis (AIH) [87-89]. 
Concerning T1D, previous research has demonstrated the presence of enteroviruses 
(EV) in pancreatic islets from patients [89]. Epidemiological studies have also reported 
more EV infections in T1D patients than in controls [89, 90]. Regarding MS, several 
epidemiological and immunological studies indicate an association with Epstein-Barr 
virus (EBV) [91-96]. However, the results remain controversial; some researchers 
provide evidence for the expression of EBV in B cells in inflamed post-mortem brain 
tissue [91], while others do not detect EBV-positive cells, or at least in very few 
patients only [97-100]. In patients with AIH, previous research demonstrates the 
presence of antibodies against hepatitis C virus (HCV), in addition to a type of 
autoantibodies called liver/kidney microsomal antibody type 1 (LKM-1) in patients 
with chronic HCV infection [87]. Notably, many of the infections associated with 
autoimmune disorders are opportunistic, primarily affecting individuals who cannot 
efficiently eradicate the virus, leading to persistent proinflammatory conditions.  
Impaired immunity and increased susceptibility to infections have also been 
demonstrated in patients with AAD in terms of reduced NK cell cytotoxicity and poor 
responses to IFNs in-vitro [101, 102]. These findings are mirrored by studies reporting 
that AAD patients have a higher intake of antibiotics and antivirals, both before and 




Autoimmune Addison’s disease 
While Addison’s disease during the last century was predominantly caused by 
tuberculous infiltration of the adrenal glands, the autoimmune form currently 
dominates in developed countries where it is responsible for approximately 80% of the 
cases in adult patients [83, 105, 106]. AAD is a classic organ-specific autoimmune 
disease characterized by an immune-mediated attack on the hormone-producing cells 
in the adrenal cortex, while the adrenal medulla remains intact. Destruction of the 
adrenal cortex leads to deficiency of the vital steroids cortisol and aldosterone, and 
patients with AAD therefore depend upon lifelong supplementation therapy [1, 107].  
The adrenal cortex 
The adrenal gland is a hormone-producing organ, composed of two cell layers with 
distinct embryological origins. The inner adrenal layer (medulla) arises from the 
ectoderm lineage and produces catecholamines (such as epinephrine and 
norepinephrine), whereas the outer adrenal cortex derives from intermediate mesoderm 
and converts cholesterol into various bioactive steroid hormones (Figure 3 and 4). The 
adrenal cortex consists of three separate zones, whereby each produces different 
steroids mediating stress response and regulation of blood pressure. The zona 
glomerulosa forms the outermost layer and produces the mineralocorticoid aldosterone, 
important for the maintenance of blood pressure. Zona glomerulosa is under the control 
of the renin-angiotensin system, which is regulated by blood pressure and changes in 
sodium and potassium levels. The next cell layer constitutes zona fasciculata that 
synthesizes glucocorticoids like cortisol under stimulation by the hypothalamic-
pituitary-adrenal (HPA) axis. Cortisol induces gluconeogenesis and anti-inflammatory 
processes during stress. The innermost zona reticularis secrete androstenedione and 
dehydroepiandrosterone (DHEA), which can further be converted to sex hormones in 
peripheral tissues [108, 109].  
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Figure 3. Adrenal anatomy. The adrenal glands are located on top of the kidneys and consist 
of the outer adrenal cortex and the inner adrenal medulla. The adrenal cortex is subdivided 
into three distinct layers: Zona glomerulosa, producing mineralocorticoids, zona fasciculata, 
secreting glucocorticoids, and zona reticularis, producing androgens. The inner medulla 
synthesizes catecholamines including epinephrine and norepinephrine. Figure produced using 
Medical Servier Art. 
Figure 4. Steroidogenesis in the adrenal cortex. Cholesterol is converted to aldosterone, 
cortisol, and androgens through different pathways that require the specific enzymes 
cholesterol side-chain cleavage enzyme (CYP11A), 17α-hydroxylase (CYP17), 3β-
hydroxysteroid dehydrogenase type 2 (3βHSD2), 21-hydroxylase (CYP21), 11β-hydroxylase 
(CYP11B1), and aldosterone synthase (CYP11B2).  
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Clinical characteristics  
AAD is a relatively rare disorder with a prevalence in European populations ranging 
from 93-220 cases per million [105, 110-114]. Like other autoimmune diseases, AAD 
affects more women (female: male ratio 1.5-3.5:1) and can occur at any age, although 
it generally affects individuals between 30 to 50 years of age [105]. Patients have 
insufficient production of the adrenal steroids due to the autoimmune attack of the 
adrenal cortex. The pathological changes can develop slowly over many years before 
the clinical manifestations appear, which include fatigue, nausea, dizziness, weight 
loss, skin hyperpigmentation, and salt-craving [105, 107, 115]. Hyperpigmentation is 
due to the absence of the cortisol-mediated negative feedback mechanism of the HPA 
axis response, leading to increased production of adrenocorticotropic hormone 
(ACTH) and pro-opiomelanocortin (precursor of ACTH), which enhances stimulation 
of the melanocortin 1 receptor of skin melanocytes [116, 117]. Salt-craving is caused 
by aldosterone deficiency, which impairs the kidney’s ability to reabsorb salt, causing 
low blood pressure. This increases the activity of renin to activate the protein hormone 
angiotensin that, in turn, tries to stimulate the release of aldosterone by the adrenals 
[115, 118]. Elevated ACTH levels and plasma renin activity are therefore important 
clinical characteristics of AAD. To correct the insufficient levels of cortisol and 
aldosterone, patients are treated with hydrocortisone and fludrocortisone, respectively 
[115].  
The dominant target of the adrenal autoantibodies seems to be the steroid cytochrome 
P450 21-hydroxylase (21OH) and has ever since its discovery in 1992 been the 
important diagnostic marker of AAD [119]. 21OH is located in the 
smooth endoplasmic reticulum (ER) of adrenocortical cells and are involved in the 
synthesis of cortisol and aldosterone (Figure 4) [120]. Autoantibodies against 21OH 
are reported to be present in >95% of patients at diagnosis in developed countries [121] 
and 86% of all Norwegian patients [122]. This high frequency, however, tends to 
decline with a disease duration greater than 20 years. Furthermore, a previous study 
reported that 21OH autoantibody-positive patients with other autoimmune 
endocrinopathies or first-degree relatives of patients with organ-specific autoimmune 
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diseases have a cumulative risk for AAD of around 50% [123]. Thus, presence of these 
antibodies may predict AAD development. Among the general population, the 
frequency of 21OH autoantibodies is approximately 0.5% [124].  
AAD may not only occur in isolation. Around 50% of AAD patients also suffer from 
other autoimmune entities such as T1D, AITD, premature ovarian insufficiency (POI), 
CD, and autoimmune gastritis [124]. The co-existence of at least two of the three 
endocrine diseases T1D, AITD, and AAD is typically referred to as APS-2 [43]. AAD 
is also frequently present in the unique disorder APS-1 (prevalence 1:90 000 in 
Norway) defined clinically by the presence of two out the three manifestations: AAD, 
hypoparathyroidism, and mucocutaneous candidiasis [125]. Whereas APS-1 is a 
monogenic disease, AAD (and APS-2) seem to have a more complex etiology 
involving multiple genes and unknown environmental factors [126].  
The genetic basis of AAD 
Investigating the genetic basis of complex diseases, such as AAD, is challenging due 
to several factors. The genotype of a patient does not necessarily correlate with the 
phenotype; phenocopies may occur, meaning that environmental factors could induce 
an AAD phenotype in a patient without known disease susceptible variants that 
matches the phenotype of a patient that does carry such variants. Additionally, AAD is 
a genetically heterogeneous disease in which variants in any one of several 
susceptibility genes may cause the same phenotype, and multiple of these may be 
necessary to produce it (polygenic inheritance). Lastly, AAD show incomplete 
penetrance, which means that certain individuals who inherit susceptibility alleles 
might not develop the disease [105].  
Despite all these complicating factors, research on monozygotic twins and familial 
clustering of AAD have revealed the existence of highly penetrant susceptible alleles 
[105, 127, 128]. The best characterized seem to be located within the HLA class II 
haplotypes HLA-DR3-DQ2 and HLA-DR4-DQ8. Polymorphisms in these haplotypes 
enable the presentation of a different repertoire of self-antigens in the peptide-binding 
pocket. Notably, individuals carrying the heterozygous combination DR3-DQ2/DR4-
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DQ8 are at higher risk than homozygotes carrying either one of the haplotypes (Figure 
5) [113, 129]. This may be due to the formation of heterodimers by the trans-encoded 
DQ molecules, increasing the functional diversity of the MHC complex [130]. HLA 
class I genes have also been associated with AAD, more specifically those that are part 
of the conserved allele combination DR3-B8 (Figure 5) [62, 63]. These alleles are 
further part of the ancestral haplotype defined as 8.1 (AH 8.1) containing the core HLA 
alleles HLA-A*01:01, -C*07:01, -B*08:01, -DRB1*03:01, -DQA1*05:01 and -
DQB1*02:01 [131]. Apart from AAD, AH 8.1 has been associated with a wide range 
of immune-mediated diseases including T1D, CD, SLE, AIH, common variable 
immunodeficiency (CVID), and IgA deficiency [132, 133].  
 
Single nucleotide polymorphisms (SNPs) in genes regulating T and B cell activation 
and differentiation are also associated with increased risk of AAD development 
(summarized in Table 1). Among these, SNPs in CTLA4 and PTPN22 (protein tyrosine 
phosphatase non-receptor type 22) appear frequently as genetic risk variants (also in 
other autoimmune disorders), underlining the importance of fine-tuning T cell 
signaling to avoid development of autoimmunity [134-137]. CTLA-4 downregulates T 
cell signaling by binding to CD80/86 on APCs, and gene polymorphisms impairing 
this mechanism may lead to reduced inhibition of T cell responses [138, 139]. PTPN22 
Figure 5. Combination of HLA alleles conferring high risk of AAD 
development. Figure produced using Genome Decoration Page (NCBI). 
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inhibits T cell activation by dephosphorylating key signaling molecules downstream of 
the TCR. This process is dependent on the binding of PTPN22 to C-terminal Src kinase 
tyrosine kinase, and SNPs (in particular c.1858C>T, p.Arg620Trp) interrupting this 
physical interaction cause lack of T cell inhibition [138, 140, 141]. Other susceptibility 
variants are located in the genes encoding BACH2 (BTB domain and CNC homolog 
2), important for B cell differentiation and generation of Tregs [129, 142]; NALP1 
(NACHT leucine-rich-repeat protein 1), promoting inflammasome assembly and 
inflammatory cytokine release [143, 144]; and CLEC16A (C-Type Lectin Domain 
Containing 16A), presumably regulating autophagy and NK cell function [145]. 
Recently, variants in AIRE were also found to be associated with AAD, at least in the 
Swedish patient cohort [146]. This finding has yet to be replicated in other populations, 
although many AAD risk loci may differ between studies of different cohorts.  
 
Table 1. Susceptible genes contributing to AAD, outside the MHC region.  
Gene Function References 
CTLA-4 Inhibits T cell responses [134], [137] 
PTPN22 
Dephosphorylates signaling molecules downstream 
of the TCR, important for T cell inhibition 
[135], [136] 
BACH2 




Promotes inflammasome assembly and 
inflammatory cytokine release 
[143], [144] 
CLEC16A Regulates autophagy and NK cell function [145] 




None of the risk genes described so far, except for HLA, seem to have a major impact 
on an individual’s genetic susceptibility to develop AAD; they only explain a small 
fraction of familial clustering. An explanation for this missing heritability problem is 
that many of the available genotyping assays focus on SNPs present in more than 1-
5% of the patient population [147]. However, the genetic architecture of AAD seems 
to be complex, involving multiple variants. An important step towards solving this 
missing heritability problem is therefore to search for rare and low-frequency variants 
with high impact. This strategy could illuminate the genetic variation in AAD, which 
is important for better prevention, diagnosis, and treatment of the disease.  
Immunopathogenesis  
The specific triggers underlying the progression of AAD from one phase to another are 
still not clear, but there have been considerable advances in our understanding of the 
pathogenesis over the past few decades.  
Histologic studies of adrenal glands from patients with AAD show a significant 
mononuclear cell infiltration and atrophy of the adrenal cortex, in addition to some 
fibrosis, while the medulla is spared [148, 149]. These data suggest that during the 
active phase of the disease there is an extensive destruction and loss of all three cell 
layers of the adrenal cortex mediated by lymphocytes, plasma cells, and macrophages 
[150]. Since AAD is primarily associated with class II HLA alleles, it seems likely that 
initiation of adrenocortical destruction depends upon activation of CD4+ T cells that, in 
turn, license autoreactive immune cell responses. As there is a potentially unlimited 
supply of self-antigens, this autoreactive immune attack may continue until the target 
organ is destroyed and replaced by fibrous tissue.  
Irreversible damage of both zona glomerulosa and zona fasciculata is what causes the 
first clinical signs of adrenal insufficiency [105, 150]. Notably, this might not be until 
90% of all adrenocortical cells are destroyed [151]. Before overt, symptomatic adrenal 
failure, however, autoantibodies against 21OH are typically present. Whether these 
autoantibodies are involved in disease progression is yet not clear, although it appears 
that they have no inhibiting effect on the 21OH enzyme in vivo [107, 150, 152]. This 
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is not that surprising since 21OH is an intracellular enzyme. Also, a previous study 
demonstrated that transplacental passage of 21OH autoantibodies from a mother with 
AAD was not sufficient to cause autoimmune adrenocortical destruction in the child 
[153]. Thus, the main mediators of the autoimmune destruction seem to be cytotoxic T 
cells, although the specific mechanisms remain unclear.  
The first indication of T cell proliferation in response to adrenal proteins was provided 
by Freeman and Weetman, using peripheral blood mononuclear cells (PBMCs) from 
AAD patients [154]. However, no individual adrenal antigens were identified. Husebye 
et al. in contrast, used BALB/c and SJL mice, immunized with recombinant 21OH, to 
demonstrate proliferation of lymph node cells to a specific 21OH-derived epitope, 
21OH342-361 [155]. A few years later, Bratland et al. showed T cell proliferation and 
IFN-γ production in response to the same epitope (21OH342-361), using PBMCs from 
AAD patients [33]. Since then, epitope mapping has suggested two specific 21OH 
epitopes targeted by circulating autoreactive CD8+ T cells. The first epitope, published 
by Rottembourg et al. [34], was mapped to the HLA-B8 restricted sequence 
EPLARLEL (21OH431-438) after performing an ELISPOT assay to detect IFN-γ 
producing T cells in response to 21OH peptides of 20 amino acids length. 
Subsequently, using MHC-peptide multimer technology, two responder patients were 
shown to have higher frequencies of EPLARLEL-specific CD8+ T cells than a HLA-
B8-positive control. A few years later, a second epitope was revealed by Dawoodji et 
al. [156]. This one was mapped to the HLA-A2 restricted sequence LLNATIAEV 
(21OH342-350). T cells specific for this sequence were reported to have the ability to lyse 
cells pulsed with the LLNATIAEV-peptide, by granzyme B secretion. Together, these 
studies suggest a central role for 21OH-specific T cells in the pathogenesis of AAD 
and open up new avenues for research into the features of these cells.  
The major and unanswered question of the immunopathogenesis is what causes the 
lymphocytic infiltration of the adrenal cortex. This issue is challenging to address 
because all histochemical analyses of adrenal glands from AAD patients are post-
mortem due to practical and ethical reasons. Also, the experimental animal models 
developed so far, have shown limited relevance to the human AAD [105]. Most studies 
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on the pathogenesis of AAD have therefore been restricted to peripheral blood and 
serum. Interestingly, evidence of lymphocytic infiltration in the adrenal gland has not 
only been limited to AAD patients. A previous study on autopsy cases of young and 
old individuals revealed that approximately 7% of the subjects less than 50 years had 
mononuclear cell infiltration within the adrenal cortex, and this frequency increased 
with age [157]. These infiltrations are most likely not significantly pathogenic, as the 
prevalence of AAD is far more rare, but it might indicate that focal infiltration of the 
adrenals does occur. In such circumstances, a healthy adrenal gland is producing a 
sufficient amount of cortisol that would ensure an anti-inflammatory milieu, protecting 
the cortex from an autoimmune attack [158]. This protective and immunosuppressive 
effect of cortisol could then help explain why AAD is a rare condition compared to 
other autoimmune endocrine disorders [105]. In that case, a key step in the 
pathogenesis of AAD could therefore be a reduction of cortisol at sites of infiltration 
(e.g. due to adrenocortical damage) which may reduce tolerance to adrenal proteins and 
lead to activation of lymphocytes. As a result, steroid production decreases along with 
increased infiltration, resulting in a vicious cycle of adrenocortical cell damage and 
steroidogenesis impairment. Together, these events may trigger an autoreactivity to 
adrenal antigens, eventually leading to a complete adrenal failure [105]. The exact 
mechanisms underlying this selective autoimmune attack and reduced cortisol 
production in AAD patients remain elusive, but it has been postulated that virus 
infection of the adrenal gland is a potent trigger [83].  
Viruses as triggers of the autoreactive immunity 
The coordinated attack of the adrenocortical cells, involving CD4+ T cells, CD8+ T cells 
and antibody-producing B cells, driven mainly by the self-antigen 21OH, is highly 
reminiscent of the specific immune response against viruses. In this context, we could 
speculate that viral infection of the adrenal gland leads to necrosis of adrenocortical 
cells, resulting in the release of self-antigens and augmentation of lymphocytic 
infiltration, causing inflammation of the adrenal cortex. This may further lead to uptake 
of self-antigens and/or viral peptides by APCs. Since 21OH and other steroid enzymes 
are among the most abundant proteins in the adrenal cortex, they are likely to be 
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presented as peptides on MHC molecules. Release, uptake, and presentation of self-
antigens (epitope spreading) can further activate autoreactive T and B cells, and thereby 
eventually lead to autoimmune adrenalitis (Figure 6) [83]. 
This hypothetical model for AAD development is supported by previous studies 
showing that the adrenals are permissive to a variety of viral agents including 
cytomegalovirus (CMV), EBV, herpes simplex virus types 1 and 2 (HSV-1/HSV-2), 
HCV and polyomaviruses [83]. Most of these viruses cause opportunistic infections 
and usually do not lead to autoimmunity, suggesting the requirement of additional host 
genetic errors and immunodeficiencies. Indeed, this seems to be the case for AAD 
Figure 6. A potential viral pathogenic mechanism in AAD. A simplified model of how 
virus infection of the adrenal cortex may lead to activation of autoreactive immune cells and 
adrenal insufficiency. First, persistent viral infection causes necrosis of adrenocortical cells 
and subsequently release, uptake, and presentation of self-antigens by APCs. Secondly, 
autoreactive T cells get activated by self-antigen presentation within local draining lymph 
nodes, which, in turn, license the activation of macrophages (M) and autoreactive B cells. 
Further necrosis and apoptosis of adrenocortical cells cause decreased cortisol production, 
increasing the lymphocyte infiltration in the adrenal cortex, eventually leading to AAD. Figure 
produced using Medical Servier Art. 
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patients, as previously mentioned [101-103, 159]. Viral pathogenic mechanisms are 
also suggested for other complex immune-mediated diseases like asthma, T1D, and 
Crohn’s disease [160]. Unlike these diseases, however, no specific pathogens have 
been identified for AAD, highlighting the need for research on viral exposure in 
affected patients. In this way, we may gain a better understanding of the pathogenesis, 
and thereby design therapies to protect susceptible individuals with inappropriate 






The overall objective of this project was to identify and functionally characterize 
genetic risk factors involved in AAD pathogenesis. To fulfill this aim, we used a two-
sided strategy: First, we validated and characterized specific mutations revealed by 
whole-exome sequencing (WES) of 142 AAD patients. Since AAD is a rare condition 
with a complex genetic basis, we set out to search for and characterize rare genetic 
variants (allele frequency <1% in the general population) predicted to- or previously 
demonstrated to be damaging, which could make up for the missing heritability 
problem in AAD. Secondly, we aimed to elucidate genetic and immunological factors 
that influence disease progression from one phase to the other. For this, we focused on 
HLA-specific immunological determinants for autoreactive T cells, as these cells are 
thought to be the main driver of adrenal gland destruction in AAD.  
The specific aims were: 
I. Validate and characterize rare TLR3 variants identified in several unrelated 
patients. 
II. Investigate clinical aspects of a patient carrying a rare homozygous nonsense 
mutation in the HSD3B2 gene.  
III. Characterize autoreactive CD8+ T cells from AAD patients to identify HLA-












In this section, the most central parts of the methodology used in the thesis will be 
discussed. A detailed description of the materials and methods can be found in the 
separate papers.  
Patient and control material  
Through the Norwegian Registry of organ-specific autoimmune diseases (ROAS), we 
have access to serum, plasma, EDTA blood, DNA and, PBMCs from almost 1000 AAD 
patients. All have signed a written informed consent approved by the Health Region 
West Ethics committee (2018/1417, 146/96-47·96). Samples from healthy controls 
were collected from blood donors provided by the blood bank at Haukeland University 
Hospital. All experiments were conducted following the declaration of Helsinki.  
Reporter gene assay (paper I) 
To determine the functional impact of the TLR3 variants revealed by WES, we studied 
the response to polyinosinic:polycytidylic acid (poly(I:C)) stimulation in cells 
transfected with constructs encoding the wild type or variant TLR3 proteins. This was 
achieved using Hek Dual Null cells, which are stably transfected with a secreted 
embryonic alkaline phosphatase (SEAP) reporter gene induced by NF-kB. As the 
endogenous TLR3 gene is specifically knocked out, all expression and activity of the 
receptor are therefore dependent on transfected TLR3. Following transfection, we 
assessed TLR3 activity by monitoring NF-kB-induced SEAP production after 
poly(I:C) stimulation, which was measured by spectrophotometry in the cell 




MHC class I/peptide multimers (paper III) 
The MHC multimer technology is a highly useful tool to detect and quantify antigen-
specific T cells from PBMCs or other sources/tissues. Recombinant MHC molecules 
are loaded with peptides of antigen proteins, which can be recognized by cytotoxic T 
cells. Several of these MHC-peptide complexes are attached to a fluorescent backbone 
that can be detected and quantified by flow cytometry [161].  
In paper III, we used MHC class I/peptide multimers (dextramers and streptamers) 
containing either HLA-A2-, HLA-B8- or HLA-C7-bound peptides. For details about 
the HLA-A2/B8-dextramers, see paper III. The MHC I-streptamers consisted of an 
HLA-C7-peptide complex attached to strep-tags, which are short peptides with binding 
affinity to a streptavidin molecule, named Strep-Tactin. Strep-Tactin molecules are 
fluorescently labeled, enabling quantification by flow cytometry.  
HLA-C typing (paper III) 
Since the HLA types of all the patients included in paper III were already estimated by 
allelic imputation by a genome-wide association study (GWAS) [162], we needed to 
find a quick and reliable way to HLA-type healthy controls. We decided to perform a 
PCR using sequence-specific primers for HLA-C7, published by Bunce et al. [163]. 
PBMCs and DNA from 51 healthy controls were then collected for HLA-typing, 
whereby 30% turned out to be positive for the HLA-C*0701 allele and thereby included 





Identification and characterization of rare Toll-like receptor 3 variants 
From the results revealed by the WES analysis including 142 AAD patients, a total 
number of 135 variants with CADD (Combined Annotation Dependent Depletion) 
scores >20 in 76 different candidate genes were detected. CADD is an in silico variant 
pathogenicity predictor, whereby scores above 20 indicate that a variant is amongst the 
top 1% of deleterious variants in the human genome [164]. 
Searching for rare and potentially damaging variants, we identified several interesting 
hits in the TLR3 gene: p.Thr59Asn (T59N), p.Gly221Arg (G221R), p.Phe351Ile 
(F351I), p.Leu742Phe (L742F) and p.Arg867Gln (R867Q). These were carried by five 
unrelated AAD patients. According to our in-house database, the variants were absent 
in Norwegian controls, whereas their allele frequencies in a cohort of Norwegian 
cancer patients were ranging from 0 to 0.0019. Similar frequencies were found in the 
genome aggregation database (gnomAD), ranging from 0 to 0.0017. Intriguingly, the 
F351I variant, detected in two unrelated AAD patients, is only reported once before (in 
Finland) according to gnomAD. R867Q has been described in a homozygous state in a 
Finnish patient with HSV encephalitis (HSE) [165]. Functional analysis indicated that 
this mutant is hypomorphic, causing a partial loss of TLR3’s function. T59N has also 
been described in a patient with HSE but did not show any effect on TLR3’s function 
when tested in vitro [166]. Using Sanger sequencing to validate the variants, we 
subsequently discovered that three of the five patients also carried a more common 
TLR3 variant (p.Leu412Phe [L412F]), previously associated with a variety of immune-
mediated diseases including cutaneous candidiasis, tick-borne encephalitis and 
increased susceptibility to CMV infection [167, 168]. L412F has also been associated 
with autoimmunity including T1D and AAD, although the data are conflicting [167, 
169, 170].  
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With one of the patients carrying both T59N and F351I, these findings revealed that 
four of the five patients had two variants each. Genotyping of the patients showed that 
all were compound heterozygotes, including one patient that was homozygous for 
L412F and heterozygous for R867Q. We further genotyped family members when 
available, revealing that three of the patients had at least one sibling that was 
heterozygous for either one of the two TLR3 variants, and some also carried both. All 
these siblings were healthy, except for one who also had AAD (heterozygous for 
T59N). 
In silico analysis of the variants demonstrated that F351, L412, L742, and R867 were 
located at highly conserved residues in the 18 species studied, suggesting that these 
four variants would be the most damaging. We further tested the functional impact of 
the TLR3 variants by studying the response to poly(I:C) in Hek Dual Null cells 
transfected with constructs encoding the wild type or variant TLR3 proteins. Consistent 
with the in silico analysis, F351I, L743F, and R867Q proved to be the most deleterious 
variants, reducing TLR3 activity by ~ 50-70%.  
For three of the patients carrying the damaging variants, PBMCs were available for 
experiments. By performing ELISA, we demonstrated an impaired immune response 
to the dsRNA analog polyadenylic:polyuridylic acid (poly(A:U)) in all three patients 
compared to healthy controls, as revealed by a significant loss in the production of 
IL28A/IFNλ2. IFNλs are among the first IFNs produced to suppress viral infection and 
are induced in a wide range of cell types by PRRs including the TLRs [171, 172].  
In addition to TLR3 variants, the WES analysis identified seven possibly damaging 
variants (both novel and previously described) among eight additional AAD patients 
in three different innate immune genes (IRF3, TICAM1 [TRIF] and IKBKE [IKKε]). 
All are involved in the TLR3-IFN signaling pathway. Interestingly, one of the detected 
IRF3 variants was the loss-of-function mutation p.Arg285Gln (R285Q) previously 
reported and extensively functionally characterized in a patient with HSE [173]. 
Likewise, one of the TICAM1 variants (p.Ser160Phe [S160F]), carried by two patients, 
has also been associated with HSE [166].  
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In summary, we discovered 13 AAD patients with inborn errors in genes involved in 
the innate immune response against viruses. 
 
Paper II:  
Coexistence of congenital adrenal hyperplasia and autoimmune Addison’s 
disease 
Among the many variants revealed by the WES analysis, we also identified a patient 
homozygous for an extremely rare variant in exon 2 of the HSD3B2 gene (frequency 
∼0.00003 in gnomAD), resulting in the exchange of the cysteine codon to a premature 
stop codon (p.Cys5Ter [C5X]). This leads to 3β-hydroxysteroid dehydrogenase type 2 
(3βHSD2) deficiency, which is a rare autosomal recessive form of congenital adrenal 
hyperplasia (CAH) [174]. Subsequent screening of ROAS identified the patient 
carrying the C5X variant; an adult female with AAD, POI, vitamin B12 deficiency, 
elevated ACTH levels on multiple occasions, and circulating 21OH- and parietal cell 
autoantibodies. She did not carry any of the risk HLA alleles associated with AAD. 
Scrutiny of old medical records revealed that she was initially diagnosed with CAH 
with hyperandrogenism and severe salt-wasting shortly after birth.  
To study her steroid profile, liquid chromatography-tandem mass spectroscopy (LC-
MS/MS) was performed of a serum sample taken after an overnight medication fast. 
Levels of all mineralocorticoids, glucocorticoids, and androgens were below the 
detection limit, except for tetrahydrocortisol (0.308 nmol/L), 5α-tetrahydrocortisol 
(0.187 nmol/L), and testosterone (0.066 nmol/L).  
Isolated 3βHSD2 deficiency causes accumulation of the Δ5-steroids pregnenolone, 17-
hydroxypregnenolone, DHEA, and DHEA-sulfate (DHEA-S) [174]. We therefore 
measured total pregnenolone, DHEA, and DHEA-S levels by ELISA from previously 
collected serum samples spanning the years 1996-2013. Nearly normal levels of 
pregnenolone and DHEA were found in samples from the first two years, but then 
levels decreased towards the subnormal levels generally seen in AAD patients. The 
level of DHEA-S was below the normal range, typical of AAD patients, at all time 
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points. Computer tomography (CT) and magnetic resonance (MR) scans, taken from 
age 43 to age 51, were re-evaluated and the adrenals were found to be in the lower 
range of normal thickness, 2-3 mm., indicating adrenocortical atrophy rather than 
hyperplasia as would be expected in case of isolated CAH.  
To the best of our knowledge, these findings constitute the first description of AAD in 
a patient with 3βHSD2 deficiency.  
 
Paper III:  
Circulating 21-hydroxylase-specific CD8+ T cells in autoimmune Addison’s 
disease are predominantly restricted by HLA-A2 and HLA-C7 molecules. 
While autoantibodies against 21OH have long been established for AAD patients, 
experimental data point to autoreactive T cells as the main effector cells in the 
adrenocortical destruction. So far, two immunodominant T cell epitopes of 21OH have 
been proposed. The first epitope, provided by Rottembourg et al. [34], was mapped to 
the HLA-B8-restricted sequence EPLARLEL, and the second epitope, published by 
Dawoodji et al. [156], was mapped to the HLA-A2-restricted sequence LLNATIAEV. 
However, data on frequencies of EPLARLEL- and LLNATIAEV-specific CD8+ T cells 
in AAD patients, and their cytokine responses to the exact epitopes, are limited. Our 
aim was therefore to address these issues using MHC class I multimers and cytokine 
analyses.  
PBMCs were isolated from patients and controls and used for experiments both ex vivo 
(day 0) and in vitro after 13 days of antigen stimulation and expansion. Initial staining 
(day 0) of cells with HLA dextramers revealed significantly higher frequencies of 
LLNATIAEV-specific CD8+ T cells in patients compared to controls. These cells also 
showed strong peptide-induced expansion in vitro after 13 days. In contrast, 
EPLARLEL-specific CD8+ T cells were almost completely absent in both patients and 
controls and did not show any ability to expand upon stimulation with cognate peptide.  
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Consistent with these results, IFNγ ELISPOT assays on both ex vivo and expanded 
cells revealed clear production of IFNγ in response to LLNATIAEV, whereas no such 
response was found for EPLARLEL-stimulated cells. Multiplex cytokine analyses 
further demonstrated production of IL-6, TNFα, MIP-1α, and MIP-1β in response to 
LLNATIAEV, but in contrast to IFNγ, these responses faded after 13 days of 
expansion. Therefore, IFNγ seemed to be the most appropriate and reliable biomarker 
for peptide-specific CD8+ T cells, especially for expanded cells.  
Having demonstrated the lack of response to EPLARLEL, we set out to identify 
alternative epitopes within the longer peptides 21OH431-450 (Rottembourg [34]) and 
21OH430-447 (Dawoodji [156]) reported to be immunodominant regions. PBMCs from 
patients and controls were stimulated with a panel of adjacent 9 amino acids-
overlapping peptides covering the longer peptide 21OH430-447 
(GEPLARLELFVVLTRLLQ). Of the peptides tested, ARLELFVVL (21OH434-442) 
induced the strongest IFNγ response among the patients. Furthermore, utilizing an 
epitope discovery system and complementary biochemical analyses, we discovered 
that ARLELFVVL did not show any affinity for HLA-B*0801, like EPLARLEL, but 
instead seemed restricted to HLA-C*0701.  
To confirm the immunodominance of ARLELFVVL, we generated an HLA-
C*0701/ARLELFVVL streptamer to investigate the frequency of ARLELFVVL-
specific CD8+ T cells in AAD patients versus controls. Intriguingly, significantly 
higher frequencies of peptide-specific cells were found in AAD patients. 
ARLELFVVL did also induce strong expansion of ARLELFVVL-specific CD8+ T 
cells in patients by in vitro stimulation for 13 days, but not in controls. PBMCs were 
also tested in ELISPOT assays ex vivo, revealing significantly stronger IFNγ responses 
to ARLELFVVL in patients than in controls. Importantly, these responses were 
comparable to the responses against the longer peptide 21OH430-447.  
Collectively, these data indicate the presence of two immunodominant CD8+ T cell-
targeted epitopes of 21OH in AAD: LLNATIAEV, presented by HLA-A2, and 






Since the discovery of Addison’s disease in 1855 by Thomas Addison [175], there have 
been considerable advances in our understanding of the pathogenesis and etiology. 
Whereas tuberculosis was the predominant cause of adrenal destruction earlier, 
autoimmune adrenalitis is now the dominating form and accounts for nearly 90% of 
cases in developed countries. It is well-established that the autoimmune form is caused 
by a complex interplay between genes and the environment, although environmental 
factors are less studied. The role for a genetic basis has been particularly evident by the 
high disease concordance in monozygotic twins and the familial clustering, suggesting 
the existence of highly penetrant susceptibility alleles [105, 127, 128]. In this project, 
we have investigated the involvement of rare susceptible alleles, with presumably 
large effects. Furthermore, based on previous genetic studies on AAD pointing out the 
HLA loci as being the most prominent genetic risk factor, we also examined HLA-
specific immunodominant epitopes of the major autoantigen 21OH.  
Involvement of inborn errors of innate immunity 
In paper I, we identified several rare missense variants in TLR3 and associated 
members of the TLR3-IFN pathway in a subgroup of patients with AAD. The 
functional impact of the TLR3 variants on the receptor’s response to viral dsRNA was 
studied utilizing a cell-based reporter assay involving poly(I:C) as the dsRNA analog. 
Of the five rare variants discovered, three were found to have significantly impaired 
function; F351I (carried by two unrelated patients) and L742F, both of which have 
never been functionally characterized before, in addition to R867Q, previously 
described to be causative (when homozygous) of HSE [165]. Patients harboring F35I 
or R867Q had healthy siblings heterozygous for the same variants, demonstrating 
incomplete penetrance. This is in line with previous studies on genetic etiologies of 
HSE also showing incomplete penetrance of TLR3 pathway deficiencies [165, 173]. 
Several factors may cause this inheritance pattern including environmental factors such 
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as infections by viruses or other pathogens, or the genetic architecture of the host, as 
well as epigenetic factors [165].  
Although inborn errors of the TLR3-IFN pathway have been shown to impair antiviral 
immune responses, previous studies are conflicting on the role of this pathway in 
protective immunity. TLR3 deficiency in fibroblast seem to impair IFN responses and 
lead to high levels of viral replication, whereas in leukocytes, TLR3-mediated 
immunity seems to be surprisingly redundant for the antiviral host defense [165, 176, 
177]. This may be due to an extensive activation of cytosolic RNA sensors, including 
MDA5 and RIG-I [178]. Nonetheless, TLR3 seems to have a clear protective role in 
the central nervous system (CNS) against HSV- and influenza A virus-induced 
encephalitis in humans [165, 179, 180]. Studies of TLR3- and TRIF-deficient mice, 
also suggest an important role for TLR3 outside the CNS, in which these mice have 
abolished IFN production and considerably higher viral load in non-neural tissues 
compared to the wild-type mice [181]. This is supported by other studies showing that 
a wide range of immunopathologies and immunological traits are associated with SNPs 
in TLR3 [167, 169, 170]. Recent findings demonstrated that TLR3-pathway deficiency 
increases the risk of autoimmune encephalitis in the weeks or months after HSE 
infection [182, 183]. Furthermore, inborn TLR3 deficiency has also been reported in 
patients with severe influenza pneumonitis [184] and herpes zoster ophthalmicus [185]. 
In conjunction, infection of TLR3-deficient mice is shown to cause T1D due to 
abrogated IFN-I responses and necrosis of virus-infected β-cells [186]. Taken together, 
the role of the TLR3 pathway seems relevant for inducing immunological phenotypes 
that eventually lead to immune-mediated diseases. Still, more knowledge about the role 
of the TLR3 pathway in antiviral immunity is needed, especially in the context of 
autoimmunity that may only occur ensuing certain infections.  
Identifying rare genetic variants that influence the development of complex diseases is 
challenging and the central question, in this case, would be if the identified variants 
play any etiological roles in AAD. Exome sequencing is a widely-used approach to 
identify low-frequency variants, but it is difficult to claim any association when only a 
few individuals are carriers. The effect of the variants may therefore seem low when 
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standing alone but could confer increased risk in combination with disease susceptible 
HLA alleles. Moreover, it is important to note that AAD has a heterogeneous genetic 
etiology, meaning that several different variants could induce the same phenotype, and 
multiple of these might be necessary to produce it. Therefore, rare variants carried by 
only some individuals might play a key role in disease development. Moreover, 
phenocopies may occur, meaning that environmental factors could induce an AAD 
phenotype in an individual without known susceptibility variants that matches the 
phenotype to an individual that does carry high-risk variants [105]. This may explain 
why the AAD patients in the current study do not exhibit any unique phenotype. At the 
same time, we might speculate that the genotype could predict the etiology of the 
disease, even though it does not correlate with the phenotype. Thus, AAD patients with 
inappropriate antiviral responses, due to inborn errors of innate immunity, may share 
the same environmental trigger such as viral infections (Figure 7).  
The suggested role of viruses in AAD is based upon previous studies showing that the 
adrenals are permissive to a variety of viral infections and that AAD patients show 
reduced NK cell cytotoxicity and poor response to IFNs in-vitro, both of which may 
cause inappropriate antiviral responses [101, 102]. Furthermore, certain genetic risk 
factors associated with AAD are variants in genes that participate in the immune 
response against infectious diseases, such as PTPN22 (also participating in TLR-driven 
type I IFN production) [135, 187-189] and BACH2 [142, 190], which together can 
affect the course of viral infections [191]. Epidemiological and cohort studies have also 
reported that AAD patients have more infections and increased use of anti-microbial 
agents (such as antivirals) than the general population, which does not correlate with 
glucocorticoid dosage [103, 192]. Moreover, a previous study of AAD patients in the 
Polish and United Kingdom cohorts showed that there is a month-of-birth effect on the 
risk of AAD development, in which the incidence of AAD peaks in the winter months. 
This may be linked to the increase of viral infections during this time of year that could 
trigger the development of AAD later on [193].  
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Identification of an extremely rare homozygous mutation 
in the HSD3B2 gene 
The steroidogenesis is a fine-tuned mechanism of the adrenal cortex that converts 
cholesterol into a variety of bioactive signaling molecules. Disturbed steroid 
biosynthesis is often associated with adrenal disorders, whereby the severity is 
depending on which steroid enzyme is being deficient. Apart from AAD, underlying 
causes of steroid enzyme deficiencies include inborn autosomal recessive mutations 
resulting in CAH [116]. In paper II we report an adult female patient with primary 
adrenal insufficiency due to both CAH, resulting from 3βHSD2 deficiency, and AAD. 
3βHSD2 deficiency is a rare autosomal recessive condition, constituting <0.5% of all 
CAH cases, and impair the first steps of steroid hormone production and sexual 
development [194]. 
At inclusion in ROAS, the patient was classified as having AAD and POI with vitamin 
B12 deficiency, and 21OH and parietal cell autoantibodies. However, genetic analysis 
revealed that she also had CAH due to an extremely rare homozygous stop-gain 
mutation in HSD3B2, representing, to our knowledge, a novel disease etiology. 
Scrutiny of old medical records further revealed the presence of small-sized adrenal 
glands instead of hyperplastic glands, as normally seen in CAH. The patient had also 
no overproduction of ∆5-steroids following elevated ACTH levels, suggesting 
complete adrenal insufficiency.  
Steroid profiling by LC-MS/MS revealed the presence of tetrahydrocortisol and 5α-
tetrahydrocortisol, which is consistent with her ongoing replacement therapy including 
hydrocortisone. Additionally, the very low, but detectable, level of testosterone may be 
due to the conversion of DHEA by 3βHSD1 in the periphery. Previously measurable 
pregnenolone levels suggest that the autoimmune destruction of the adrenal cortex 
commenced sometimes in the 1990-ties. However, her initial steroid levels were not 
above the normal range as would be expected in case of isolated 3βHSD2 deficiency, 
and may indicate an even earlier initiated adrenocortical destruction. The treatment of 
CAH, starting only 1 week after birth, could have masked the classical manifestations 
of complete adrenal insufficiency resulting in delayed diagnosis of AAD. Hence, the 
 55 
diagnosis of AAD could not be confirmed from symptoms, but only by detecting 21OH 
autoantibodies.  
According to literature, we could only find one reported case of CAH occurring 
together with complete adrenal insufficiency suspected to be AAD. This patient, 
however, did not have 21OH autoantibodies or HLA risk alleles but was weakly 
positive for autoantibodies against 17α-hydroxylase [195]. Therefore, it is conceivable 
that there might be other rare unreported cases of AAD due to early diagnosis of CAH, 
masking the clinical symptoms of adrenal insufficiency. Notably, several other AAD 
patients included in our WES analysis were heterozygous carriers of rare missense 
variants in HSD3B2. Although family members of CAH patients, carrying 
heterozygous HSD3B2 mutations, seem to have maintained normal 3βHSD2 activity 
in vivo [196], genetic variations in HSD3B2 are associated with other conditions such 
as idiopathic hypospadias and prostate cancer [197, 198].  
Apart from HSD3B2 variants, WES also revealed heterozygous missense variants in 
the steroidogenesis-related genes CYP11A and STAR (unpublished data). Additionally, 
our group has previously detected several exonic and intronic variants in CYP21A2 
(encoding 21OH) in AAD patients, but as all were in linkage disequilibrium (LD) with 
high-risk HLA-DR alleles they were not considered as independent risk factors [199]. 
However, it is possible that such subtle molecular abnormalities and inborn errors of 
steroidogenesis could lead to decreased negative feedback inhibition of the HPA axis 
and hence elevated levels of ACTH (seen in AAD and CAH patients). Since ACTH 
regulates expression of steroidogenesis-related genes [200], this in turn may upregulate 
transcription of steroidogenic enzymes including 21OH, potentially leading to ER 
stress and accumulation of misfolded proteins, and/or generation of novel adrenal 
antigens presented by stressed adrenocortical cells. In combination with viral 
infections, this could have biological consequences and contribute to inflammation and 
immunological destruction of the adrenal cortex (Figure 7).  
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Immunodominant HLA-restricted epitopes of 21OH in AAD 
In paper III, we were able to detect significantly higher frequencies of LLNATIAEV-
specific CD8+ T cells in AAD patients than in controls, utilizing isolated PBMCs and 
MHC class I dextramers. These cells also displayed a stronger ability of IFNγ 
production and clonal expansion compared to controls upon stimulation with cognate 
peptide. This could reflect a previous antigen experience in vivo in an inflammatory 
setting, and thus the CD8+ T cells in AAD patients would have a more memory-like 
phenotype. Likewise, autoreactive T cells in T1D patients are previously demonstrated 
to be skewed towards a memory phenotype, whereas those detected in healthy controls 
seem to be predominantly naïve [201, 202]. 
Surprisingly, we did not detect any significant T cell response to EPLARLEL in terms 
of low frequencies of EPLARLEL-specific CD8+ T cells and weak peptide stimulated 
IFNγ production. Neither did they show any ability to expand upon peptide stimulation. 
This lack of response spurred us on to investigate alternative immunodominant 
epitopes. Having found that AAD patients showed positive IFNγ responses against the 
longer peptide GEPLARLELFVVLTRLLQ (21OH430-447), we tried to map alternative 
epitopes using short, overlapping peptides. Strong T cell responses were detected to 
peptide 5 (21OH434-442, ARLELFVVL), but this epitope did not show affinity for HLA-
B*08:01 (like EPLARLEL) according to an epitope discovery system. We therefore 
started to search for alternative HLA class I molecules able to present this peptide, with 
a particular emphasis on those encoded by AH 8.1, containing the predisposing HLA-
B8, -DR3, and -DQ2 alleles. 
The extended form of AH 8.1 is usually defined by the haplotype HLA-A*01:01, -
C*07:01, -B*08:01, -DRB1*03:01, -DQA1*05:01 and -DQB1*02:01 [131]. This 
combination has been highly conserved throughout evolution, hence HLA-B*0801 is 
in strong LD with the class I alleles HLA-C*0701 and -A*0101. Using the NetMHC 
4.0 server for HLA peptide binding prediction, ARLELFVVL was predicted to bind 
HLA-C*0701. Following generation of C7*ARLELFVVL streptamers, we managed 
to detect high frequencies of ARLELFVVL-specific CD8+ T cells in several HLA-C7 
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positive patients, but not in HLA-C7 positive controls. These cells also displayed the 
ability of clonal expansion and IFNγ production upon stimulation with ARLELFVVL, 
suggesting antigen experience in vivo. Intriguingly, these ARLELFVVL-specific 
responses were comparable to the responses to GEPLARLELFVVLTRLLQ, 
suggesting that the reactivity against the longer peptide are primarily directed against 
ARLELFVVL, and not EPLARLEL as previously suggested. Detection of both 
LLNATIAEV- and ARLELFVVL-specific CD8+ T cells supports the hypothesis that 
the autoimmune reaction in AAD is triggered by various epitopes of 21OH (Figure 7) 
[105]. This would require a broad MHC peptide-binding repertoire, which is in line 
with why the heterozygous combination of the DR3-DQ2 and DR4-DQ8 haplotypes, 
increasing the variety of MHC molecules, confers higher risk of disease development 
than a homozygous combination of either of the haplotype [63, 203]. This seems also 
to be the case for T1D, in which the risk of disease development is greater in individuals 
expressing the heterozygous genotype (DR3-DQ2/ DR4-DQ8), presumably because 
DQ heterodimers facilitate presentation of several different beta cell antigens [204].  
DR3, DQ2, and HLA-C7 are all part of AH 8.1, as previously mentioned, which confers 
risk of developing a wide range of immune-mediated diseases. Nonetheless, AH 8.1 
has been highly conserved through generations and is today one of the most common 
haplotypes in northern Europe [132, 133]. Carriers of AH 8.1 might develop aberrant 
immunity including increased antibody production and decreased NK cell activity 
[132, 205, 206]. Increased antibody production is in line with AAD, and other AH 8.1-
associated autoimmune disorders, being characterized by the presence of 
autoantibodies, even though they often are characterized by Th1-mediated immune 
responses [132]. Also, decreased NK activity fits well with the previous finding that 
AAD patients seem to have reduced NK cell cytotoxicity, potentially making them 
more vulnerable to viral infection [102]. The various immune dysfunctions arising 
from AH 8.1 suggest involvement of several genes beyond the classical high-risk HLA 
alleles, such as C4 (involved in the complement cascade), IKBL (involved in the 
regulation of NF-kB) and TNF (involved in inflammatory conditions) [132, 133]. 
However, the independent impact of these genes has been difficult to determine due to 
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the strong LD within AH 8.1. Many studies have therefore focused on HLA to 
understand key events of autoimmune pathologies.  
Of the AH 8.1-associated HLA class I alleles, HLA-B8 stands out as an important 
autoimmune-prone factor, whereas HLA-C7 has received little attention [207]. Our 
study seems therefore to represent the first demonstration of an HLA-C7 restricted 
epitope in the context of autoimmune diseases. The limited focus on HLA-C, in 
general, may be due to its low expression, but maybe more importantly because of the 
strong LD with the predisposing HLA-B, -DR and DQ that makes it difficult to detect 
any independent associations for individual HLA variant loci [63, 133, 208]. However, 
since AH 8.1 is so well conserved and seems unique in its association with several 
autoimmune diseases [132, 133, 209], it is conceivable that HLA-C7 to some extent 
does contribute to disease susceptibility. Besides, a growing number of publications 
have demonstrated that HLA-C alleles, including C7, play a role in T1D, SLE, and RA 
[204, 208, 210-215]. For instance, the HLA-C*0602 allele is a major risk factor in 
psoriasis by which CD8+ T cells react to epitopes derived from streptococcal M 
proteins and type 1 keratin, presented by HLA-C*0602 [216]. However, the majority 
of the HLA-C/autoimmunity associations are not linked to antigen-presentation, but 
rather the capacity of HLA-C to act as a ligand for killer cell Ig-like receptors (KIRs), 
expressed by NK cells [207].  
KIRs and HLA-C interact to regulate the cytotoxic activity of NK cells, ensuring a 
balanced immune response and self-tolerance [207, 217]. Polymorphisms of KIRs and 
HLA can therefore disrupt this balance, potentially leading to inflammation and 
autoimmune diseases later on [218]. Concerning HLA-C7, its role in autoimmune 
diseases has been particularly evident in patients with both T1D and CD, where it 
contributes to elevated levels of the weak inhibitory KIR ligand C1 [215]. 
Predominantly weak regulation and inhibition of NK cells could lead to higher 
cytotoxic activity and inflammation, accelerating an initiated autoimmune process. 
With regards to AAD, excessive NK activity does not seem to play a major role in the 
autoimmune attack of the adrenal cortex, especially since NK cells seem rather 
impaired in some AAD patients [102]. On the other hand, it has been demonstrated that 
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HLA-C7 zygosity affects NK cells’ cytotoxicity, whereby homozygotes for HLA-C7 
have a lower frequency of NK cells with lytic activity than heterozygotes [219]. We 
may therefore envisage that it is the HLA-C7 zygosity in AAD patients (carrying AH 
8.1) that impairs their NK cell cytotoxicity, and further make them vulnerable to viral 
infection, which may trigger AAD later on. Therefore, as well as being an 
immunodominant antigen-presenting molecule shown in this study, HLA-C7 might 
also contribute to AAD development by affecting innate immune responses.  
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Figure 7. A model for the pathogenesis of AAD. Inborn errors of innate immunity could 
cause persistent viral infection and lead to necrosis of adrenocortical cells and subsequent 
release of 21OH and other autoantigens engulfed by APCs. Next, autoreactive T cells get 
activated by self-antigen-presentation by APCs within local draining lymph nodes, which, in 
turn, license the activation of autoreactive T and B cells with specificities for 21OH and/or 
other adrenocortical antigens. Circulating 21OH-specific CD8+ T cells, recognizing the 
immunodominant epitopes LLNATIAEV presented by HLA-A2 or ARLELFVVL presented 
by HLA-C7, produce IFNγ to stimulate their cytotoxicity and motility and cause further 
necrosis and apoptosis of adrenocortical cells, leading to decreased cortisol production. 
Besides, inborn errors of steroidogenesis-related genes may influence the pathogenesis 
through altered ACTH stimulation of steroidogenic enzyme synthesis. This may cause ER 
stress and/or generation of novel antigens presented by stressed adrenocortical cells. 
Altogether, these events may result in inflammation and increased lymphocyte infiltration of 





The conclusions to the work in this doctoral dissertation are as follows: 
I. Several AAD patients carry rare and damaging variants in the TLR3-IFN 
signaling pathway, some of which impair the TLR3 signaling function in 
response to dsRNA (poly(I:C)).  
II. TLR3 pathway deficiencies affect the patients’ IFN production, potentially 
making them more susceptible to viral infections. 
III. The identified TLR3 variants show incomplete penetrance as several siblings of 
the patients were healthy carriers, which is consistent with previous studies 
demonstrating that the penetrance of TLR3 pathway deficiencies are incomplete 
for HSE.  
IV. We report the first description of a patient with complete adrenal insufficiency 
due to both AAD and 3βHSD2 deficiency caused by an extremely rare variant 
in the HSD3B2 gene. To our knowledge, this combination represents a novel 
disease etiology. 
V. Unreported cases of AAD may exist due to early diagnosis of CAH, masking 
the clinical symptoms of autoimmune adrenalitis.  
VI. AAD patients have significantly high frequencies of CD8+ T cells reacting to 
the previously reported HLA-A2-restricted 21OH epitope LLNATIAEV 
(21OH342-350).  
VII. LLNATIAEV-specific CD8+ T cells display a strong ability of clonal expansion 
and cytokine production (including IFNγ) in response to its cognate peptide, 
compared to healthy controls.  
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VIII. CD8+ T cells specific for the proposed HLA-B8-restricted 21OH epitope 
(21OH431-438) EPLARLEL, were almost absent in all the AAD patients tested. 
Neither did the epitope induce significant IFNγ response or CD8+ T cell clonal 
expansion.  
IX. We have identified a new immunodominant region of 21OH, ARLELFVVL 
(21OH434-442), detected in a large proportion of HLA-C7-positive patients. 
Following stimulation with ARLELFVVL, all patients exhibited clear CD8+ T 
cell clonal expansions and IFNγ production.  
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Future perspectives 
This thesis demonstrates the presence of several inborn errors in innate immunity 
among patients with AAD, which might indicate that they have impaired immune 
response against viruses in terms of deficient IFN production. Given these findings and 
previous experimental data, one of the most important future tasks would be to confirm 
if there is a true association between viral infection and autoimmune adrenalitis. 
Currently, we are analyzing the viral exposure among AAD patients utilizing a Virscan 
analysis. Virscan is a high-throughput method to analyze antiviral antibodies from sera 
using immunoprecipitation and DNA sequencing of a bacteriophage library displaying 
peptides covering the whole human virome. This analysis might enable us to sort out 
specific viral candidates potentially initiating adrenocortical autoimmunity. 
Furthermore, it is desirable to perform adrenal cortex small-needle biopsies via 
endoscopic ultrasound in AAD patients to evaluate presence of virus particles and viral 
nucleic acids in adrenocortical tissue. However, as this procedure is rather invasive, it 
may face ethical challenges.  
Another interesting follow-up study would be to investigate the response of PBMCs 
and fibroblasts from AAD patients, in particular from those with variants in the TLR3-
IFN signaling pathway, to in vitro exposure to live viruses. Such studies could provide 
answers to whether AAD patients, in general, have aberrant immune responses against 
live viruses, as well as how genetic deficiencies of innate immunity influence the 
pathogenesis of AAD. Moreover, prospective studies should be carried out, as they 
would be invaluable to discover key events between infections and signs of adrenalitis 
or adrenal insufficiency. Individuals with a strong family history of AAD could then 
be followed from birth to disease onset to monitor their viral exposure in relation to 
signs of adrenal impairment. If a role for viruses in AAD can be proved and specific 
viral candidates can be identified, vaccines or antiviral drugs would be obvious choices 
to protect susceptible individuals and to prevent disease development.  
In paper III of the present study, we report the identification of a new immunodominant 
epitope, ARLELFVVL, restricted by HLA-C7, as well as confirming the presence of 
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HLA-A2*LLNATIAEV-specific CD8+ T cells in AAD patients. Future research 
should investigate whether LLANTIAEV and ARLELFVVL promote expression of 
HLA-A2 and HLA-C7, respectively, in the adrenal cortex. Since hyperexpression of 
HLA class I is observed in pancreas samples from T1D patients [220], it is conceivable 
that the same mechanism can occur in AAD, influencing the CD8+ T cell-driven 
destruction of adrenocortical cells. As we are planning to perform 
immunohistochemical staining of adrenocortical tissue from deceased AAD patients, 
we could stain for HLA-C7 and HLA-A2 molecules to see if they are hyper-expressed. 
Furthermore, the cytotoxic potential of ARLELFVVL-specific CD8+ T cells should be 
explored to assess wether they lyse HLA-C7/ARLELFVVL-expressing cells, as shown 
for HLA-A2-restricted CD8+ T cells recognizing LLNATIAEV [156]. 
It will also be important for future studies to perform a comprehensive investigation of 
the phenotypic characteristics of ARLELFVVL- and LLNATIAEV- specific T cells, 
using the established HLA-multimer reagents. Recent advances in next-generation 
sequencing technologies have made it possible to examine the clonality and diversity 
of such T cells on a single-cell level. Utilizing MHC class I multimer technology to 
sort these antigen-specific T cells, followed by single cell immune profiling to identify 
the cells’ TCR sequences, we can assess whether they have an identical antigen 
specificity and gene rearrangement, as well as analyzing their transcriptomes.  
Elucidating the diversity of 21OH autoreactive T cells would aid our understanding of 
disease mechanisms, as well as facilitate the use of these cells as disease biomarkers 
and therapeutic targets for intervention at a stage when the majority of adrenocortical 
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A B S T R A C T
Autoimmune Addison's disease (AAD) is a classic organ-specific autoimmune disease characterized by an immune-
mediated attack on the adrenal cortex. As most autoimmune diseases, AAD is believed to be caused by a com-
bination of genetic and environmental factors, and probably interactions between the two. Persistent viral in-
fections have been suggested to play a triggering role, by invoking inflammation and autoimmune destruction.
The inability of clearing infections can be due to aberrations in innate immunity, including mutations in genes
involved in the recognition of conserved microbial patterns. In a whole exome sequencing study of anonymized
AAD patients, we discovered several rare variants predicted to be damaging in the gene encoding Toll-like re-
ceptor 3 (TLR3). TLR3 recognizes double stranded RNAs, and is therefore a major factor in antiviral defense. We
here report the occurrence and functional characterization of five rare missense variants in TLR3 of patients with
AAD. Most of these variants occurred together with a common TLR3 variant that has been associated with a wide
range of immunopathologies. The biological implications of these variants on TLR3 function were evaluated in a
cell-based assay, revealing a partial loss-of-function effect of three of the rare variants. In addition, rare mutations
in other members of the TLR3-interferon (IFN) signaling pathway were detected in the AAD patients. Together,
these findings indicate a potential role for TLR3 and downstream signaling proteins in the pathogenesis in a subset
of AAD patients.
1. Introduction
Autoimmune Addison's disease (AAD), is a chronic endocrine disorder
characterized by an immunological attack on the hormone-producing cells
in the adrenal cortex [1]. The self-antigen 21-hydroxylase (21-OH) seems to
be the dominant target of adrenal autoantibodies and autoreactive T cells
[1–3]. The underlying causes of AAD are complex, involving both genetic
and environmental factors. So far, the best characterized genetic factors are
related to antigen presentation and T cell regulation, like certain HLA
combinations and common variants in the genesCTLA4 and PTPN22 [4–6].
Most of these genetic risk factors are shared with other organ-specific
autoimmune diseases, including type 1 diabetes (T1D), celiac disease and
thyroiditis, which often co-occur with AAD in patients with autoimmune
polyendocrine syndrome type 2 (APS-2). On very rare occasions AAD can
also be monogenic, as part of autoimmune polyendocrine syndrome type 1
(APS-1), and caused by mutations in the AIRE gene encoding the autoim-
mune regulator protein [7]. However, apart from HLA genes and AIRE, the
genetic factors discovered so far are only moderately increasing the
susceptibility to develop AAD. In particular, the clustering of AAD in some
families suggest the existence of highly penetrant AAD susceptibility alleles
[8,9], but the specific alleles remain elusive. The involvement of rare var-
iants in the pathogenesis of AAD is in line with AAD being a rare disorder,
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andmayprovide an explanation to themissing heritability problemofAAD.
A possible strategy would therefore be to search for rare genetic
variants (allele frequency <1% in the general population) affecting the
phenotype [10].
Previous studies have demonstrated that errors in innate immunity
are associated with autoimmunity [11–14]. Recent findings by others
and us have suggested that alterations in the innate immune response
might be present in AAD as well [15–17]. Persistent viral infections have
further been proposed to act as triggers for immunopathological tissue
destruction, resulting in autoimmune disease [11,13]. To detect and
eliminate infectious agents, the innate immune system uses several
recognition systems, including pattern-recognition receptors (PRRs) [18,
19]. Some of the best characterized PRRs are the toll-like receptors
(TLRs), which are not only expressed in innate immune cells, but also in
the parenchyma of different organs such as the endocrine glands
[19–21]. In particular, amongst the ten human TLR paralogs, single
nucleotide polymorphisms (SNPs) and rare variants in the TLR3 gene
have been associated with several immune mediated diseases and
different outcomes of infections [11,22–27]. TLR3 is localized intracel-
lularly, within endosomes, and recognizes double-stranded RNA
(dsRNA), which is the viral replication intermediate in most viruses and
the actual genome in others [28,29]. Binding of dsRNA by TLR3's ecto-
domain initiates a signaling cascade resulting in activation of interferon
(IFN) regulatory factor (IRF)-3/IRF-7 and nuclear factor kB (NF-kB) that
stimulates cytokine production [22,30]. Mutations in TLR3 or associated
key-members of the TLR3-IFN pathway, may cause sporadic cases of
herpes simplex virus type-1 (HSV-1) encephalitis (HSE) [31]. Both
dominant and recessive mutations have been described, but incomplete
clinical penetrance has been observed for most genetic etiologies of HSE.
In the present work we have identified several rare TLR3 variants in
AAD patients, and characterized these with a novel NF-kB-based reporter
assay. Some of these variants have not previously been functionally
characterized. In addition, peripheral blood mononuclear cells (PBMCs)
from patients with TLR3 variants were stimulated with dsRNA to
examine any impairment of IFN production.
2. Materials and methods
2.1. Patients and controls
The initial patient cohort consisted of 142 AAD patients that were
subjected to whole-exome sequencing (WES). All patients were diag-
nosed with AAD based on clinical criteria as recommended by the
Endocrine Society [32], and were recruited from the National Registry of
Organ-specific Autoimmune Diseases (ROAS) at Haukeland University
Hospital, Norway. The control group consisted of an in house database
containing 308 exomes sequenced in research projects with no link to
AAD or related phenotypes. We also compared our results with those
from 795 exomes available from the Norwegian Cancer Genomics Con-
sortium (NCGC) website (http://www.cancergenomics.no). This dataset
contains more than 1.5 million individual variants coming from 1590
normal chromosomes of various cancer patients [33].
2.2. Ethics
The study was approved by the Regional Ethics Committee, project
numbers 2013/1504, 2015/2053 and 2018/1417, and informed consent
was obtained from each patient and family member included in the
study.
2.3. Blood samples and DNA extraction
EDTA blood samples from patients and controls were used for puri-
fication of DNA and for the isolation of PBMCs. Genomic DNA was
extracted from whole blood in house, using a QIAamp DNA Blood Mini
Kit (Qiagen), or performed by the Nord Trøndelag Health study (HUNT)
biobank (Levanger, Norway). Blood samples were kept at 80 C until
DNA extraction using theMasterPure™DNA purification kit version II B1
(Epicentre). Concentration of extracted DNA were normalized to 50 ng/
μl. PBMCs were isolated from whole blood using Ficoll density gradient
centrifugation, and were cryopreserved at 150 C.
2.4. Whole-exome sequencing
WES was done on an Illumina HiSeq (Illumina), after exome capture
with the Roche Nimblegen SeqCap EZ Exome Library V2 kit (Roche Di-
agnostics Corporation). The sequences were aligned to the reference
human genome (hg19) by using bwa mem (v0.7.12, [34]). The align-
ments were then refined by the Genome Analysis Toolkit (GATK, Version
2.8, [35,36]) and PCR duplicates were marked by Picard (v1.124,
http://broadinstitute.github.io/picard). The variants were called by
UnifiedGenotyper by GATK (Version 2.8, [35,36]) and annotated by
Annovar (v2017Jul16, [37]). Filtering of the exome variants was done in
FILTUS [38]. To identify rare variants, we applied filters removing var-
iants with allele frequencies greater than 1% in any of the databases
gnomAD, 1000 Genomes Project, or our in house database.
2.5. Validation of WES results and follow-up of patients
Confirmation of the detected TLR3 variants were obtained by Sanger
sequencing using BigDye Terminator v1.1 Cycle Sequencing Kit (Applied
Biosystems). Family members of selected patients were sequenced using
the same sequencing kit. PCR was performed using AmpliTaq Gold™
DNA Polymerase with Gold Buffer and MgCl2 (Applied Biosystems). For
one of the patients, no DNA from family members was available. To
determine the haplotype of this patient, exon 4 of TLR3 was amplified
from genomic DNA and cloned into pCRTM2.1-TOPO vector, using TOPO
TA cloning kit (Invitrogen) following the manufacturer's instructions.
One Shot TOP10 chemically competent E. coli cells (Invitrogen) were
transformed with cloned vector according to the manufacturer's recom-
mendations, and plated onto ampicillin containing plates and grown
overnight at 37C. Plasmid DNA from single colonies were then ampli-
fied, purified using ExoProStar 1-Step enzymatic clean up system (GE
Healthcare Life Sciences), and sequenced as described above. All primer
sequences used for PCR and Sanger sequencing were designed using
Primer3web version 4.0.0 and are available upon request.
2.6. In silico predictions
To estimate the degree of evolutionary conservation of the identified
TLR3 variants, 18 protein sequence homologs to the human TLR3 protein
were aligned using the MUSCLE (Multiple Sequence Comparison by Log-
Expectation) method [39] and ran by Jalview multiple sequence analysis
workbench version 2.10.4b1. The specific areas containing the variants
of interest were aligned separately to avoid using gaps in the alignment.
Furthermore, the variants of TLR3 and the TLR3/IFN signaling
pathway detected in patients were classified by the in silico variant
pathogenicity predictors SIFT [40], PolyPhen2 [41], MutationTaster2
[42], PROVEAN [43] and CADD [44]. In particular, CADD score > 20
was used as a threshold for classifying variants as potentially damaging.
The structural implications of the F351I mutant were also analyzed
using The PyMOL Molecular Graphics System v. 1.5 [45]. The x-ray
crystallography structures of the ectodomains of human and mouse TLR3
[46,47] were used as templates.
2.7. Cell culture
HEK-Dual Null (NF/IL8) cells (InvivoGen) were grown in DMEM (1X)
þ GlutaMax (Life Technologies) supplemented with 10% (v/v) fetal
bovine serum (Life Technologies), 50 U/ml penicillin, 50 μg/ml strep-
tomycin (Sigma Aldrich) and 100 μg/ml Normocin (InvivoGen) at 37 C
with 5% CO2 in a humidified incubator. These cells are stably transfected
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with two different reporter genes (Secreted embryonic alkaline phos-
phatase (SEAP) and the Lucia luciferase) inducible by NF-kB and IL-8,
respectively, and are triply knocked out for TLR3, TLR5 and the TNF
receptor genes.
2.8. Plasmids and site-directed mutagenesis
The following SNPs in Human TLR3 cDNA in pCMV6-Entry/TLR3
(OriGene) were produced using the QuickChange site-directed muta-
genesis kit (Strategene): T59N, G221R F351I, L412F, L742F and R867Q.
The mutagenic primers were designed with PrimerX and are available
upon request. All SNPs were confirmed by Sanger sequencing.
2.9. Reporter gene assay
HEK-Dual Null (NF/IL8) cells were harvested and plated in 6-well
plates (6  105 cells/well) for 24 h. The cells were then transiently
transfected with a mixture of the Lipofectamine 2000 reagent (Thermo
Fisher Scientific) and plasmids pCMV6-Entry/TLR3 (OriGene) encoding
the full-length wild type (WT) gene, and/or TLR3mutants. The cells were
then incubated for 48 h, before being harvested and plated in a Micro-
Amp Optical 96-well Reaction Plate. 100 μg/ml of polyinosinic-
polycytidylic acid (poly(I:C)) (Invivogen) were then added to each
well. The cells were allowed to incubate for 22–24 h to reach 70–80%
confluency. 20 μl of cell supernatant of each well were then mixed with
180 μl of SEAP-inducer compound (InvivoGen) according to the manu-
facturer's protocol. The SEAP activity was assessed by reading the optical
density (OD) at 620–655 nm after 2 h. The units of SEAP activity were
normalized to untreated controls within the same transfection, and the
activity of the mutant TLR3 proteins was measured as a percentage of
activity relative to the WT protein.
2.10. Western blots
Hek-Dual Null (NF/IL8) cells were transiently transfected with WT or
mutant TLR3 as described above. The cells were then harvested and lysed
using cOmplete Lysis-M buffer 0 (Sigma Aldrich), the lysates were
centrifuged, and the supernatants obtained. The protein concentration of
the supernatants was estimated using a DC protein assay kit (Bio-Rad)
and equal amounts of protein were then mixed with LDS sample buffer
(4X) (Life Technologies/Invitrogen) and Sample Reducing Agent (10X)
(Life Technologies/Invitrogen). After 10 min at 70 C, the samples were
loaded on a NuPAGE 10% Bis-Tris Gel (Novex) and blotted onto poly-
vinylidine difluoride membrane (Invitrogen). The membrane was incu-
bated with a mouse anti-DDK (FLAG) monoclonal antibody (clone
OTI4C5, Origene). Mouse anti-GAPDH (clone 6C5, Millipore) was used as
loading control. Bands were visualized using secondary horseradish
peroxidase-conjugated goat anti-mouse antibody (Invitrogen) and the
ECL system (Thermo Scientific).
2.11. PBMC stimulations
Cryopreserved PBMCs from patients, family members and controls,
were thawed and plated onto 24-well plates (2  106 cells/well) and
stimulated with either poly(I:C) (100 μg/ml) or polyadenylic-
polyuridylic acid (poly(A:U)) (10, 50 and 100 μg/ml) for 24 h. The
production of cytokines in the supernatants was determined by ELISA kits
according to the manufacturer's instructions. These included IL28A/
IFNλ2, IFNγ (both from BioLegend) and IFNβ (R&D systems).
2.12. Statistical analysis
In order to estimate whether rare and possibly damaging variants in
TLR3were enriched among AAD patients, we compared the proportion of
individuals carrying variants with CADD scores above 20 in our AAD
cohort with the appropriate ethnic subpopulations of the Genome Ag-
gregation Database (gnomAD), using a two-sided Fisher's exact test. Only
exomes from controls were used for the analysis. All data from experi-
ments using HEK-Dual Null (NF/IL8) cells are expressed as means of at
least three independent experiments. All collected data were then tested
by an ordinary one-way analysis of variance (ANOVA), followed by
Dunnett's multiple comparisons test. To test for IL28A/IFNλ2 differences
between controls and patients, multiple t-tests were used followed by the
Holm-Sidak method to correct for multiple comparisons. For all tests, P<
0.05 was considered statistically significant. All statistical analyses were
performed with GraphPad Prism v.8.0.1 software.
3. Results
3.1. General findings of WES
Initially, we searched for variants in a candidate list of 194 genes
(available upon request) related to 1) APS-1 disease manifestations apart
from AAD (e.g. chronic mucocutaneous candidiasis), 2) AIRE, molecular
partners of AIRE, or related genes, 3) other autoimmune diseases or
syndromes consisting of autoimmune manifestations, and 4) steroido-
genesis, vitamin D metabolism, or adrenal disorders. A total number of
135 variants with CADD scores> 20 in 76 different genes was detected in
the patients. 94 patients carried at least one variant (ranging from 1 to 6),
while 38 patients did not carry any rare variants. The results from the last
10 patients were excluded from further analysis as the sequencing data
failed to pass quality control. No significant findings were noted with
regard to total number of coding variants, or enrichment of rare variants
in any of the list of 194 candidate genes. However, when searching for
rare and potentially damaging variants, we identified several interesting
hits in TLR3. A complete list of all detected rare variants with CADD
Table 1
Overview of patients with TLR3 variants. Abbreviations: AAD ¼ autoimmune Addison's disease; APS-2 ¼ autoimmune polyendocrine syndrome type 2; F ¼ female;
Het ¼ heterozygous; Hom ¼ homozygous; M ¼ male; T1D ¼ type 1 diabetes.
Patient Sex Autoimmune disease Age of onset HLA status Affected relatives TLR3 variants (NM_003265.2) Zygosity
P1 M Isolated AAD 22 High risk c.176C > A (p.Thr59Asn) Het
c.1051T > A (p.Phe351Ile) Het
Brother: AAD c.176C > A (p.Thr59Ans) Het
Brother: T1D
P2 M Isolated AAD 24 Neutral c.1051T > A (p.Phe351Ile) Het
c.1234C > T (p.Leu412Phe) Het
Cousin: T1D
P3 F Isolated AAD 33 High risk c.1234C > T (p.Leu412Phe) Hom
c.2600G > A (p.Arg867Gln) Het
Mother: hypothyroidism
P4 M Isolated AAD 47 Neutral c.1234C > T (p.Leu412Phe) Het
c.2224C > T (p.Leu742Phe) Het
P5 F APS-2 þ celiac disease 19 High risk c.661G > A (p.Gly221Arg) Het
Father: T1D
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scores > 20.0 can be found in Supplementary Table 1.
3.2. Five TLR3 missense variants in five unrelated patients with AAD
WES revealed five rare TLR3 (transcript NM_003265.2) missense vari-
ants in five AAD patients: c.176C > A, c.661G > A, c.1051T > A (in two
patients), c.2224C > T and c.2600G > A, leading to the predicted amino
acid changes p.Thr59Asn, p.Gly221Arg, p.Phe351Ile, p.Leu742Phe and
p.Arg867Gln, respectively. In the following these variantswill be referred to
as T59N, G221R, F351I, L742F and R867Q. None of these variants were
detected among the 308 exomes in our in house database, but some were
present at low frequencies in the NCGC exome database (summarized in
Table 2). Using Sanger sequencing to validate the variants, we discovered
that three patients carrying the F351I, L742F and R867Q single nucleotide
variants (SNVs), respectively, also carried the more common TLR3 variant
c.1234C> T (p.Leu412Phe), fromhere on referred to as L412F.One patient
carried both the T59N and the F351I variant. Therefore, four of the five
patients had two variants each. All variants, except G221R, were present at
low frequencies in gnomAD,which includes data from~140,000 unrelated
individuals [48]. G221R was absent in gnomAD, but was detected in a
single allele in the Avon Longitudinal Study of Parents and Children
(ALSPAC) cohort as part of the UK10K consortium [49]. The F351I variant
detected in two AAD patients, is extremely rare, with only one allele
(detected in Finland) deposited in gnomAD. T59N and R867Q have previ-
ously been implicated in HSE. R867Q has been described in homozygous
combination in a Finnish patient with HSE, and was shown to be a hypo-
morphic allele resulting in a partial form of autosomal recessive TLR3
deficiency [31], and T59N was detected in a HSE patient along with a rare
variant in the TANK-binding kinase 1 (TBK1) gene, but did not confer any
impairment on TLR3 function in vitro [50].
3.3. Clinical features of patients with rare TLR3 variants
The five patients carrying TLR3 variants, three males and two fe-
males, were all typical AAD patients (Fig. 1 and Table 1): All had auto-
antibodies against 21-OH and 3/5 had the HLA class II genotype (DR3-
DQ2/DR4.4-DQ8) conferring the highest risk of developing AAD [5].
Patient 1, 2, 3 and 4 (P1–P4) had isolated AAD, while Patient 5 (P5) had
APS-2 consisting of AAD, T1D and hypothyroidism, as well as celiac
disease. P1–P3 and P5 reported a family history of organ-specific auto-
immunity, including AAD in a brother of P1. P1–P3 did not report any
serious viral infections, but P1 and P2 had records of recurrent upper
respiratory tract infections requiring antibiotics. P1 had also been
suffering from chronic sinusitis that required surgery. P4 died in 2016 at
the age of 87, probably due to cardiac arrest, and no follow-up study
could be done for this patient. The patient had been admitted to hospital
care with possible L2-L3 fracture and lower respiratory tract and urinary
infections shortly prior to his death.
For P1–P3, DNA was available from family members (Fig. 1B). The
brother of P1 was diagnosed with AAD and carried T59N, whereas the
brother diagnosed with T1D harbored two WT alleles. The unaffected
father carried F351I. Four additional healthy siblings were also
sequenced; three were heterozygous for T59N and one of them carried
F351I. The latter, a seemingly healthy brother of P1, tested negative for
21-OH autoantibodies. For P2, the mother and one sibling were geno-
typed. Both of them were heterozygous for L412F, and both were
healthy. P3 was homozygous for L412F and heterozygous for the hypo-
morphic R867Q variant. Unfortunately, the patient's mother who was
diagnosed with hypothyroidism was deceased and therefore no DNA was
available for genotyping. Two healthy siblings were genotyped, whereby
one was heterozygous for L412F variant, and the other homozygous, in
addition to being heterozygous for R867Q. This sibling was negative for
21-OH autoantibodies. In order to genotype P4, we used a TOPO cloning
kit, revealing that also L412F and L742F were positioned on opposite
alleles. Collectively, the results indicated that the variants in P1–P4 were




































































































































































































































































































































































































































































































































































































































S. Aslaksen et al. Journal of Translational Autoimmunity 1 (2019) 100005
4
heterozygous for R867Q), hence no WT variant was present (Fig. 1A).
3.4. In silico studies of the variants
Sequence alignment analysis of the six TLR3 variants indicated that
F351, L412, L742 and R867 were highly conserved in the 18 species
studied, whereas T59 and G221 were less conserved, especially among
the fish species (Fig. 2). Thus, based on evolutionary conservation, F351I,
L412F, L742F and R867Q would be expected to be more damaging than
T59N and G221R.
T59N, G221I, F351I, L742F and R867Q were all classified by the in
silico pathogenicity prediction tools SIFT, PolyPhen2, MutationTaster,
PROVEAN and CADD, through the respective web services (Table 2). A
schematic diagram of the TLR3 protein is presented in Fig. 3. T59N,
G221R, F351I and L412F are all located in different parts of the ecto-
domain of TLR3, which is essential for the recognition and direct binding
of dsRNA at acidic pH [51,52]. L742F is located in the linker region,
which bridges the transmembrane domain and the TIR domain [31].
Furthermore, R867Q is located in the TIR domain essential for the
interaction with TRIF and thus the intracellular signal transduction upon
binding of dsRNA [31,51]. All these variants, especially F351I, L412F,
L742F and R867Q could potentially have a negative impact on the
function of the TLR3 protein.
When taking into account all the alleles containing TLR3 variants
predicted to be damaging (CADD score > 20), we found 6/264 (2.27%)
AAD patients and 213/26926 (0.79%) controls of Swedish and North
Western European origin. This difference was significantly different
(Odds ratio, 2.92 (95% CI 1.38–6.37), two-sided P value ¼ 0.02). The
difference was also significant when comparing rare variants in TLR3 in
AAD patients (6/264, 2.27%) and Norwegian exomes of the NCGC
database and our in house database (19/2206, 0.86%): Odds ratio, 2.68
(95% CI 1.12–6.77, two-sided P value ¼ 0.043).
3.5. Effects of variants on TLR3 activity
To determine the functional impact of the six variants, we studied the
response to poly(I:C) stimulation in cells transfected with constructs
encoding the WT or variant TLR3 proteins. This was achieved using Hek
Dual Null cells, stably transfected with a SEAP reporter gene induced by
NF-kB. As the endogenous TLR3 gene is specifically knocked out, all
expression and activity of the receptor is therefore dependent on trans-
fected TLR3. Stimulation of TLR3, and subsequent activation of NF-kB, is
achieved by treating the cells with a TLR3 ligand such as poly(I:C). The
units of SEAP activity were normalized to untreated controls within the
same transfection, and the activity of the mutant TLR3 proteins was
measured as a percentage of activity relative to the WT protein.
T59N, G221R and L412F demonstrated approximately the same level
of activity as WT TLR3 (Fig. 4A). F351I had reduced activity by ~70% (P
< 0.001), L742F had reduced activity by ~ 50% (P < 0.01), and R867Q
had reduced reporter activity by ~ 55% (P < 0.01) which increased to ~
60% together with L412F (P < 0.001) compared to the WT. Thus,
consistent with the in silico studies, the F351I, L742F and R867Q TLR3
variants were dysfunctional.
Although TLR3 exists as a monomer in solution, dimerization is
required in order for TLR3 to bind dsRNA [53]. To examine whether the
WT allele could rescue the activity of dimers in presence of the mutants,
we performed co-transfections of equal amounts of both variants and WT
(Fig. 4B). The WT protein fully restored the function of TLR3 when
expressed togetherwith the variants, except fromT59N and L742F, which
still showed reduced activity, but without being statistically significant.
To mimic the patients' genotypes, in which all variants were located
on opposite alleles, four different co-transfections were performed. These
included (1) constructs encoding T59N together with constructs encod-
ing F351I (P1), (2) constructs encoding F351I together with constructs
encoding L412F (P2), (3) constructs encoding L412F together with
constructs encoding both L412F and R867Q (P3), and (4) constructs
encoding L412F together with constructs encoding L742F (P4) (Fig. 4C).
The F351I, L742F and R867Q TLR3 proteins combined with L412F
showed a significant reduction in receptor activity by 40–45% (P< 0.001
for all combinations).
3.6. Expression of the TLR3 variants
The reduction or complete loss of TLR3 activity caused by the mu-
tations could be an effect of low protein expression/stability, or of an
impairment of a specific function. To examine the protein expression of
Fig. 1. TLR3 genotypes and pedigrees for AAD patients with
rare TLR3 variants. (A) Overview of the five unrelated AAD
patients carrying TLR3 variants (red). P1–P4 were compound
heterozygous for two TLR3 variants (except for the homo-
zygous state of L412F in P3), whereas P5 was heterozygous
for one variant, G221R. (B) Family pedigrees of P1, P2 and
P3, with allele segregation. Individuals affected by AAD or
T1D are shown in black or grey, respectively. Healthy rela-
tives are shown in white. Since P3 was homozygous for
L412F, genotyping of parents was omitted. Mother of P1 and
father of P2 were not genotyped.
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Fig. 2. Sequence alignment of TLR3 from multiple species and conservation of the identified variants. Alignment of the TLR3 region in humans and the corresponding
regions in the other 17 species studied, containing the six identified variants. The conserved amino acids where the variants are located are shaded in purple.
S. Aslaksen et al. Journal of Translational Autoimmunity 1 (2019) 100005
6
the TLR3 variants, we performed a Western blot using Anti-DDK (FLAG)
as the primary antibody (Fig. 4D). The results from three independent
experiments demonstrated that the expression levels of all variants
(T59N, G221R, F351I, L412F, L742F and R867Q) were comparable with
the WT. Thus, the decrease in activity was most likely not an effect of
altered expression levels.
3.7. Impaired responses to dsRNA in PBMCs from patients with TLR3
variants
For P1–P3, wewere able to collect live PBMCs for functional studies. For
stimulation experiments with PBMCs, we chose to use the alternative TLR3
ligand poly(A:U) over poly(I:C). There are several additional receptors for
dsRNA, in particular in PBMCs, and poly(A:U) has been shown to be more
exclusive to TLR3 than poly(I:C) [54]. PBMCs from P1, P2 and P3, as well as
three healthy blood donors with onlyWT TLR3 alleles, were stimulatedwith
increasing amounts of poly(A:U). The secretions of different IFNs into the cell
culture supernatant were thenmeasured using ELISA. For IFNβ and IFNγ the
productionwas eitherundetectable ornodifferenceswereobservedbetween
patients and controls (results not shown). The secreted levels of IL28A/IFNλ2
were also relatively low (1–10 pg/ml), but a dose dependent response was
observed for the controls but not the patients (Fig. 5). For the highest dose of
poly(A:U), 100 μg/ml, the difference between patients and controls was
significant (P< 0.01 for fold change and P< 0.05 for absolute levels). Thus,
the PBMCs fromAADpatientswith certain combinations of deleteriousTLR3
variants are functionally impaired in response to dsRNA.
3.8. Structural analysis of the F351I TLR3 variant
Since the structure of the ligand-binding ectodomain of TLR3 has
been solved by x-ray crystallography, we were able to analyze the
structural implications of the rare and predicted deleterious variant,
Fig. 3. Schematic presentation of the TLR3 protein with functional domains. Model of the TLR3 protein with the location of each identified variant, and the different
domains (leader sequence (L), 24 leucine-rich repeats (LRRs), the transmembrane domain (TM), linker region (LR) and Toll/interleukine-1 receptor (TIR) domain).
Fig. 4. Activity and expression of the WT and mutated TLR3 alleles. (A) Activity levels were determined by TLR3-dependent reporter expression induced by NF-kB in
TLR3-deficient Hek-Dual Null cells transfected with various TLR3 proteins (WT TLR3, T59N, G221R, F351I, L412F, L742F, and R867Q mutant TLR3), followed by
stimulation with 100 μg/ml poly(I:C). Activity levels are presented as percentages relative to the activity of the WT protein. An ordinary one-way analysis of variance
(ANOVA), followed by Dunnett's multiple comparisons test was used to test for statistical differences between WT and mutated TLR3 proteins (**P < 0.01). (B)
Activities of the WT alone and combined with the TLR3 mutated proteins, transfected in equal amounts. (C) Activity of the WT and co-transfected TLR3 mutants
mimicking the genotype of the four patients carrying two different variants (***P < 0.001). (D) A representative Western blot showing the expression of WT and TLR3
mutants in Hek-Dual Null cells. The cells were transfected with plasmids encoding the WT or the mutated TLR3 proteins listed above the gel image.
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F351I. The F351 residue is part of a phenylalanine spine that helps
stabilize the interior of the convex face of the horseshoe-shaped ter-
tiary structure of the TLR3 ectodomain (Fig. 6A, B). This particular
structural feature are conserved in many of the TLR proteins, but also
in other proteins containing leucine rich repeat (LRR) domains [55,
56]. Changing the phenylalanine at residue 351 to an isoleucine will
not only disrupt the spine of consecutive phenylalanines, but perhaps
also destabilize the convex shape of the TLR3 ectodomain by steric
effects (Fig. 6C).
3.9. Additional rare variants in the TLR3-IFN signaling pathway in AAD
patients
Asmutations in a number of genes in the TLR3-IFN pathway have been
described to result in impaired TLR3 signaling [57], we reexamined our
WES data to search for rare variants in these genes in AAD patients. Spe-
cifically, we searched for variants in the genes IKBKE, IKBKG, IRF3, TBK1,
TICAM1, TRAF3 and UNC93B, as none of these were among our original
candidate list of 194 genes. As with TLR3, we focused on variants with
frequencies less than 1% in gnomAD, 1000GP and our in house exome
database, that received a CADD score >20. Both novel and previously
described variants were discovered in IRF3, IKBKE and TICAM1 (Table 3).
Intriguingly, one AAD patient carried the previously described c.854G> A
(p.Arg285Gln) mutation in IRF3, from here on referred to as R285Q. This
autosomal dominant mutation, leading to haploinsufficiency, has previ-
ously been reported in an adolescentwithHSE [58]. Furthermore, twoAAD
patients had a variant in TICAM1, whereby one of the variants (c.479C> T
(p.Ser160Phe)) also has been described in an adult patient with HSE [50,
59].
4. Discussion
In the present study, we have identified and characterized several rare
variants in TLR3 and associated members of the TLR3-IFN signaling
pathway in patients with AAD. The discovery of mutations in these genes
indicates that inborn errors of immunity could influence the genetic
susceptibility to develop AAD.
Our exome sequencing approach revealed five rare missense variants
in TLR3 in five different AAD patients. All variants were absent in healthy
Norwegian controls, whereas their allele frequencies in a cohort of
Norwegian cancer patients were ranging from 0 to 0.0019. Similar fre-
quencies were found for the TLR3 variants in the gnomAD database,
ranging from 0 to 0.0017. To study if the identified variants displayed an
impaired response against viral dsRNA in general, we designed and
established a cell-based reporter assay using poly(I:C) as the stimulating
factor. Of the five rare missense variants discovered, three were found to
have significantly impaired function; F351I, an extremely rare variant
carried by two of our patients, L742F, which has, together with F351I,
Fig. 5. PBMC responses to stimulation with dsRNA. IL28/
IFNλ levels (fold change) were determined by ELISA in cell
culture supernatants of PBMCs obtained from P1–P3 (red)
and three healthy controls (blue). The cells were either
unstimulated (NS) or stimulated with 10, 50 or 100 μg/ml
poly(A:U) for 24 h. Broad and narrow horisontal bars show
the mean and standard deviation, respectively, for each
group per condition. Multiple t-tests were used to test for
statistical differences between patients and controls, followed
by the Holm-Sidak method to correct for multiple compari-
sons (**P < 0.01).
Fig. 6. Consequences of the F351I variant
on TLR3 ectodomain protein structure. (A)
Overview of the TLR3 ectodomain with the
phenylalanine spine in purple (F351 in red).
The importance of consecutive aromatic
amino acids, in particular phenylalanine, in
this regard is probably due to the favorable
action of π-electrons on top and below the
aromatic rings. This excess of electrons gives
the face of the ring a small net negative
charge, while the hydrogen atoms on the
edge of the ring gets a correspondingly small
positive charge. The aromatic rings of the
consecutive phenylalanines therefore
interact with each other with their rings in
parallel but slightly offset so that the edge of
each ring is interacting with the face of the
next. (B) Close-up view of F351 (in red) and
two of its neighbouring phenylalanines. (C)
Modelling of the F351I variant (in yellow),
indicating both a disruption of the phenyl-
alanine spine, but probably also steric hin-
drance in the interior of the TLR3
ectodomain.
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never been functionally characterized before, and R867Q, previously
described to be causative (when homozygous) of HSE [31]. The reduced
activity was probably not due to low levels of translated protein, as
Western blot analyses revealed approximately the same levels of variant
proteins as the WT. Instead, we believe that the variants displaying
impaired function are disrupting key functional domains of the TLR3
protein. Using the available crystal structures of the TLR3 ectodomain,
we were able to model the structural consequence of the F351I variant. It
appears that F351 is a crucial part of the phenylalanine spine of the
ectodomain, which serves to stabilize the interior of the convex side of
the domain. Switching F351 into a non-aromatic amino residue, such as
isoleucine, could therefore be detrimental to the stability of the ecto-
domain. Unfortunately, no structural analysis could be made of L742F
and R867Q, as these residues are located in domains of TLR3 that have
not yet been structurally solved. It is possible that the exchange of the
leucine at position 742 with a phenylalanine may affect the protein's
stability, solubility, oligomeric state and proteolytic resistance [60].
Variants in this region have been reported as possibly pathogenic before,
in particular the G743D variant in cis with the R811I variant was shown
to result in autosomal dominant TLR3 deficiency by haploinsufficiency in
a HSE patient [31]. The exchange of an arginine to an asparagine at
position 867 makes the mutant protein partially dysfunctional [31]. The
previous reporting of R867Q as a hypomorphic allele is consistent with
our functional characterization of the variant.
Interestingly, four of the five patients carrying rare TLR3 variants
were compound heterozygous for an additional TLR3 variant, except
for the homozygous state of L412F in P3. For patients P2–P4, these
genotypes resulted in an impaired signaling activity in our in vitro
reporter assay. For three of the patients the additional allele was the
common L412F variant which has been associated with a wide range
of aberrant immune responses, including an APS-1-like phenotype
characterized by cutaneous candidiasis, increased susceptibility to
cytomegalovirus infections and autoimmunity, including AAD and
hypothyroidism [61]. However, the L412F variant was not found to be
associated with AAD in a Polish cohort of 168 AAD patients [62]. In
our functional characterization of the TLR3 variants, we could not
detect any functional defect of L412F compared to the WT, which is in
agreement with some previous reports [63], but in contrast to others
[64,65]. On the other hand, L412F did not rescue the TLR3 activity
when co-expressed with the hypomorphic alleles F351I, L742F and
L412F þ R867Q. Finally, we demonstrated that PBMCs from P1–P3
had impaired responses to dsRNA, as revealed by a significant loss in
production of IL28A/IFNλ2.
Although TLR3 deficiency and other inborn errors of the TLR3-IFN
signaling pathway have been shown to confer defects in innate immu-
nity, their ascribed clinical phenotypes appear surprisingly narrow.
Apart from infections of the CNS by HSV-1, HSV-2 and probably varicella
zoster virus (VZV), potentially leading to encephalitis, TLR3 and asso-
ciated partners appear functionally redundant for immunity against most
other viruses [63,66]. This may be due to the extensive activation of
cytosolic RNA sensors, including MDA5 (encoded by the gene IFIH1) and
RIG-I [67], when TLR3 is deficient. At the same time, a wide range of
immunopathologies and immunological traits have been associated with
common polymorphisms in TLR3 [68], strongly suggesting that genetic
variations in TLR3 induce immunological phenotypes that eventually
lead to immune-mediated diseases.
Interestingly, in addition to variants in TLR3, we also identified AAD
patients carrying previously described variants in genes encoding other
proteins in the TLR3-IFN signaling pathway: The autosomal dominant
variant R285Q in IRF3 [58], and several other, both rare and novel,
missense variants in IRF3, TICAM1 and IKBKE.
Identifying rare genetic variants that drive the onset of a disease is
challenging, and a central question here would be if the identified var-
iants in the TLR3-IFN signaling pathway play any etiological roles in
AAD. Importantly, approaches typically used for testing associations of
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underpowered for rare variants [69]. Although numerous studies have
demonstrated the ability of WES to identify low frequency variants
associated with autoimmune disease, it is difficult to conclude any as-
sociation when only a few individuals carry the variants. In addition,
studying the genetic basis of complex diseases such as AAD is challenging
because the genotype of a patient does not necessarily clearly correlate
with the phenotype; phenocopies may occur, meaning that environ-
mental factors could induce an AAD phenotype in a patient without
known disease susceptible variants that matches the phenotype of a pa-
tient that does carry such variants. This may explain why none of our
patients carrying TLR3 variants, exhibit a unique phenotype compared to
the other 127 AAD patients. Hence, several different variants could
induce the same phenotype, and multiple of these may be necessary to
produce it [8]. On the other hand, even though the genotype does not
correlate with the phenotype, we could speculate that it may predict the
etiology of the disease. In that case, patients with damaging variants in
innate immune genes may share the same triggers, such as viral in-
fections, initiating or perpetuating the immunological attack of adrenal
tissue [70].
Another caveat in our study is the presence of the TLR3 variants in
unaffected carriers and family members, indicating incomplete pene-
trance, which is a common phenomenon for mutations associated with
AAD [8]. The impact of rare TLR3 variants may therefore seem relative
subtle when standing alone, but could confer an increased risk of
developing AAD when present together with HLA risk alleles. In this
regard, it should be noted that the patients (P1 and P3) sharing TLR3
genotypes with healthy siblings, both carried the HLA class II haplotypes
giving the highest risk to develop AAD. However, incomplete penetrance
seems to characterize the majority of mutations in the TLR3 pathway
causing HSE, especially for the autosomal dominant mutations involving
haploinsufficiency [57,58].
Taken together, our findings support that decreased or aberrant
antiviral defense is associated with risk for AAD. This observation is
consistent with previous research showing that patients with primary
adrenal insufficiency have higher intake of antimicrobial agents, espe-
cially antifungal and antiviral drugs, and increased hospital admission
as a result of infection compared to controls [17]. Moreover, the adrenal
cortex has previously been shown to be permissive to a variety of viral,
fungal and bacterial agents [71–75]. Decreased resistance or inappro-
priate responses to viruses can therefore lead to a persistent viral
infection in the adrenal glands, resulting in destruction of adrenocor-
tical cells, which may initiate an autoimmune process [1]. AAD may
therefore only develop if there is an adrenal infection that effectively
triggers the condition. The specific pathogens involved in this process,
however, are yet to be discovered. Interestingly, experimental infections
with HSV-1 in mice have shown that the adrenal cortex is among the
first locations colonized by the virus [74]. Given the previous shown
association between TLR3 mutations and HSE, we tested for an
increased susceptibility to HSV-1 infections in AAD affected individuals.
However, no significant difference in IgM and IgG antibodies against
HSV-1 between patients and healthy controls was detected (data not
shown).
In conclusion, this study provides the first identification of several
rare and damaging variants in the TLR3-IFN pathway in patients with
AAD and highlights the significance of studying the interplay between
genes and viral infections in immune mediated diseases.
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Background: Underlying causes of adrenal insufficiency include congenital adrenal
hyperplasia (CAH) and autoimmune adrenocortical destruction leading to autoimmune
Addison’s disease (AAD). Here, we report a patient with a homozygous stop-gain
mutation in 3β-hydroxysteroid dehydrogenase type 2 (3βHSD2), in addition to impaired
steroidogenesis due to AAD.
Case Report: Whole exome sequencing revealed an extremely rare homozygous
nonsense mutation in exon 2 of the HSD3B2 gene, leading to a premature stop
codon (NM_000198.3: c.15C>A, p.Cys5Ter) in a patient with AAD and premature
ovarian insufficiency. Scrutiny of old medical records revealed that the patient was
initially diagnosed with CAH with hyperandrogenism and severe salt-wasting shortly after
birth. However, the current steroid profile show complete adrenal insufficiency including
low production of pregnenolone, dehydroepiandrosterone (DHEA) and DHEA sulfate
(DHEA-S), without signs of overtreatment with steroids.
Conclusion: To the best of our knowledge, this is the first description of autoimmune
adrenalitis in a patient with 3βHSD2 deficiency and suggests a possible association
between AAD and inborn errors of the steroidogenesis.
Keywords: adrenal insufficiency, congenital adrenal hyperplasia, 3β-hydroxysteroid dehydrogenase type 2
deficiency, autoimmune adrenalitis, autoimmune Addison’s disease
INTRODUCTION
3β-hydroxysteroid dehydrogenase type 2 (3βHSD2) catalyzes the conversion of 15-steroids into
14-steroids (Figure 1). Deficiency of 3βHSD2 causes a rare autosomal recessive form of congenital
adrenal hyperplasia (CAH) characterized by high levels of pregnenolone, 17-hydroxypregnenolone,
dehydroepiandrosterone (DHEA), DHEA sulfate (DHEA-S), and androstenediol, and lack of
cortisol, aldosterone, and androstenedione (1). There are two isozymes of 3βHSD encoded by
HSD3B1 andHSD3B2. 3βHSD2 is expressed in the gonads and the adrenal cortex, whereas 3βHSD1
is expressed in peripheral tissues, converting circulating DHEA to testosterone (1). 3βHSD2
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FIGURE 1 | Steroidogenesis in the adrenal cortex. Cholesterol is converted to aldosterone, cortisol, and androgens through different pathways that require specific
enzymes [cholesterol side-chain cleavage enzyme (CYP11A), 17α-hydroxylase (CYP17), 3β-hydroxysteroid dehydrogenase type 2 (3βHSD2), 21-hydroxylase (CYP21),
11β-hydroxylase (CYP11B1), and aldosterone synthase (CYP11B2)]. Androstenedione and testosterone are further converted to dihydrotestosterone (DHT) and
estrogens in peripheral tissue.
FIGURE 2 | Levels of circulating 21OH autoantibodies in the patient (P1) and steroid profiling. (A) Using radioimmunoprecipitation assay, levels of 21OH
autoantibodies (blue) were measured in serum samples taken at different time points from 1996 to 2013. The cut-off value (red) was set to obtain the maximal
accuracy as calculated by an interlaboratory study (6). (B) Using ELISA, levels of pregnenolone, DHEA, and DHEA-S were measured in serum samples from the
patient (P1, blue) taken from different time points from 1996 to 2013. Normal adult values (green) are based on established reference values from the textbook
“Gynecologic Endocrinology” (pregnenolone) (7), hormone laboratory at Oslo University Hospital (DHEA) (https://ehandboken.ous-hf.no/api/File/GetFile?entityId=
105475) and hormone laboratory at Haukeland University Hospital (DHEA-S) (https://analyseoversikten.no/analyse/14). The average value of AAD patients (yellow) is
measured from serum samples of patients included in our biobank.
deficiency can therefore cause relatively high levels of
testosterone in females, whereas it cannot compensate for
the absence of adrenal and gonadal synthesis of testosterone
in males. This causes ambiguous genitalia in males, whereas
female newborns exhibit mild virilization or normal sexual
differentiation, and may remain undiagnosed until a salt-wasting
crisis occurs (1–3).
Adrenal insufficiency can also be due to autoimmune
adrenalitis, or autoimmune Addison’s disease (AAD),
characterized by an immunological attack of the adrenal
cortex leading to decreased production of cortisol and
aldosterone (4). The self-antigen 21-hydroxylase (21OH) is
the dominant target of adrenal autoantibodies and autoreactive
T cells (4). Therefore, autoantibodies against 21OH and
Frontiers in Endocrinology | www.frontiersin.org 2 September 2019 | Volume 10 | Article 648
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low serum cortisol levels are important diagnostic markers
for AAD.
To the best of our knowledge, we here report the first patient
affected by both inborn 3βHSD2 deficiency and acquired AAD.
CASE REPORT
A whole-exome sequencing study involving 142 AAD patients
(5) revealed a patient with a rare homozygous mutation
in exon 2 of HSD3B2 [frequency ∼0.00003 in the Genome
Aggregation Database (gnomAD)] at nucleotide position
15 (NM_000198.3:c.15C>A), resulting in the exchange of
the cysteine codon to a premature stop codon (p.Cys5Ter).
Subsequent screening of the Norwegian Addison Registry
identified the patient harboring the mutation, a 55-year-
old female with AAD, premature ovarian insufficiency and
vitamin B12 deficiency, accompanied by 21OH- and parietal
cell autoantibodies (Figure 2A). Notably, she did not carry
any of the major histocompatibility complex (MHC) alleles
conferring high risk to develop AAD (4). She tested negative
for other autoantibodies such as anti-thyroid peroxidase, and
had normal levels of thyroid stimulating hormone (0.40–
4.50 mIU/L). Scrutiny of early medical records showed that
TABLE 1 | Steroid profile of the patient.
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she exhibited hyperpigmentation of genitalia and clitoris
hypertrophy already at birth. One week of age, she started
to vomit and developed hyponatremia (127 mmol/L) and
hyperkalemia (6.1 mmol/L). Elevated levels of 17-ketosteroids
were detected. She was therefore diagnosed with CAH
and supplemented with cortisone acetate and eventually
fludrocortisone. Her sister had also been diagnosed with
CAH, but unfortunately died in an adrenal crisis at 2 years
of age.
Given these conflicting findings, computer tomography
(CT) and magnetic resonance (MR) scans, taken from age 43
to 51, were re-evaluated and the adrenals were found to be
in the lower range of normal thickness 2–3mm, indicating
adrenocortical atrophy rather than hyperplasia as would be
expected in case of isolated CAH. We then obtained a steroid
profile by liquid chromatography tandem mass spectroscopy
(LC-MS/MS) of a serum sample taken after an overnight
medication fast (Table 1). Levels of all mineralocorticoids,
and most glucocorticoids and androgens were below the
detection limit, except for tetrahydrocortisol (0.308 nmol/L),
5α-tetrahydrocortisol (0.187 nmol/L), and testosterone
(0.066 nmol/L). Total pregnenolone, DHEA and DHEA-S
levels were measured by enzyme-linked immunosorbent
assay (ELISA) from previously collected serum samples
spanning the years 1996–2013 (Figure 2B). Normal levels of
pregnenolone and DHEA were found in samples from the
first 2 years, but then levels decreased toward the subnormal
levels generally seen in AAD patients. DHEA-S was also
below the normal range, typical of AAD patients, at all time
points. ACTH was measured at several time points, revealing
elevated levels on multiple occasions. The highest levels were
observed in 2011 at 130 pmol/L (normal range 2.0–11.6
pmol/L). Importantly, we detected no subsequent increase in
pregnenolone, DHEA, and DHEA-S in spite of elevated ACTH
levels (Figure 2B).
She is currently, at age 57, treated with 20mg hydrocortisone
(PlenadrenTM) and 100 µg fludrocortisone, and does not have
suppressed ACTH-values.
DISCUSSION
This is the first report of a patient with primary adrenal
insufficiency due to both 3βHSD2 deficiency and AAD. At
inclusion in the national Addison registry, she was classified
as having AAD with vitamin B12 deficiency, and 21OH-
and parietal cell autoantibodies. However, genetic screening
and scrutiny of old records revealed a rare form of CAH
due to a stop-gain mutation in HSD3B2. The presence of
small sized adrenal glands instead of hyperplastic glands,
normally seen in CAH, and no overproduction of ∆5-steroids
following elevated ACTH levels, suggest that the adrenal
cortex is not functioning. Presence of tetrahydrocortisol
and 5α-tetrahydrocortisol is consistent with her ongoing
replacement therapy which includes hydrocortisone. The
low, but detectable, level of testosterone may be due to
conversion of DHEA by 3βHSD1 in the periphery. Previously
measureable pregnenolone levels suggest that the autoimmune
destruction of the adrenal cortex commenced sometimes in
the 1990-ties.
According to literature, we could only find one reported
case of CAH occurring together with complete adrenal cortex
insufficiency suspected to be autoimmune adrenalitis. This
patient, however, had neither 21OH autoantibodies, nor MHC
risk alleles, but was positive for autoantibodies against 17α-
hydroxylase (8). Therefore, we speculate there might be other
rare unreported cases of autoimmune adrenalitis due to early
diagnosis of CAH, masking the clinical symptoms of AAD.
Interestingly, several other AAD patients included in our exome
sequencing analysis carry rare heterozygous non-synonymous
variants in HSD3B2 (Table 2). Although it appears that family
members of CAH patients, carrying heterozygous HSD3B2
mutations, maintain normal 3βHSD2 activity in vivo (14), genetic
variations in HSD3B2 are associated with other conditions such
as idiopathic hypospadias and prostate cancer (15, 16). Therefore,
both subtle molecular abnormalities and deleterious mutations
in HSD3B2 could have biological consequences, and may play a
role in the pathogenesis of the immune-mediated adrenocortical
destruction in AAD.
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